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CHAPTER ONE 
INTRODUCTION 
 
The protein alpha-synuclein (α-syn) can be found at the root of many overlapping 
neurodegenerative diseases. These conditions have been grouped together and termed, 
Lewy Body Diseases (LBDs). Included in this group of neurodegenerative diseases are: 
Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with Lewy 
Bodies (DLB) [1] and Multiple System Atrophy (MSA) [2, 3]. Parkinson’s disease is the 
most prominent and affects greater than 1% of the population over the age of 60, making 
it one of the most common neurodegenerative diseases [4-7]. Overall these diseases 
affect greater than 5 million people across the globe [2]. The incidence of PD alone has 
increased greatly in the past decade as the general population ages and average lifespan 
continues to increase.  Unfortunately, the treatment for PD has not kept pace with the 
burgeoning patient population and neurologists have been left prescribing L-3,4-
dihydroxyphenylalanine (L-DOPA), the dopamine precursor which has been the standard 
of care for PD since the 1960s [8].     
The progressive and pathological accumulation of alpha-synuclein is the main 
characteristic linking all LBDs [2, 3, 9, 10]. Previously published studies have shown that 
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alpha-synuclein oligomers, or small aggregates, are toxic to cells in-vivo as well as in 
culture and that this toxicity can be passed from affected neurons to neighboring cells 
[11-14]. An understanding of the mechanism by which alpha-synuclein oligomers induce 
a cellular pathology that can be spread to surrounding cells will lead to a better 
understanding of the pathology underlying PD as well as a target for possible 
containment of the cellular damage [15-17].   
Biochemical studies of alpha-synuclein have shown that when alpha-synuclein 
binds to lipid membranes it undergoes a structural transition to become an amphipathic 
alpha-helix [16, 18, 19]. This adoption of an alpha-helical shape also leads alpha-
synuclein to induce membrane curvature, tubulation and disruption [20, 21]. These 
observations are remarkably similar to previous studies of adenovirus protein VI [22, 23]. 
Adenovirus, a non-enveloped virus,  enters the cytoplasm of cells by disrupting the 
endocytic vesicles by utilizing a protein that the virus encodes for termed protein VI 
following internalization of the virus [24]. Protein VI also adopts an amphipathic alpha-
helical conformation, the same structure and conformation of alpha-synuclein, which has 
been shown to be capable of disrupting and tubulating artificial liposomes [25] in a 
similar manner as alpha-synuclein. The vesicular disruption mediated by protein VI of 
the endocytic vesicle facilitates adenoviral infection, by allowing the virus access to the 
cytoplasm and nucleus.  However, this rupture is sensed by the target cell as a “danger 
signal”, resulting in a cathepsin B dependent increase in cellular reactive oxygen species 
(ROS) [23] as well as NOD-like receptor family pyrin domain containing 3 (NLRP-3) 
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inflammasome activation [26, 27]. Alpha-synuclein oligomers have been shown to be 
internalized via the endocytic pathway [28, 29], the same pathway cells use to take up 
adenovirus.  However, it remains unclear what occurs immediately following alpha-
synuclein endocytosis.  Alpha-synuclein is found in the cellular cytosol, so it must escape 
the endosome. The relationship between the escape of alpha-synuclein and the pathology 
induced by alpha-synuclein in vitro or PD pathology in vivo [17] is unknown.  
Given the structural similarities between alpha-synuclein and protein VI, we have 
hypothesized that the functions of these similar proteins would coincide.   
Leading us to believe that alpha-synuclein would be able to generate a related 
rupture of intracellular vesicles and induce comparable downstream consequences such 
as ROS production in the affected cells. Indeed, from the data collected we were able to 
observe that addition of alpha-synuclein aggregates to neuronal cell lines induces the 
rupture of endocytic vesicles, specifically lysosomes, in neuronal cells that had taken up 
the protein aggregates. This lysosomal rupture induced a cathepsin B dependent increase 
in ROS in these neuronal cell lines. Notably, larger aggregates generated using alpha-
synuclein with the E46K familial mutation did not induce the same degree of vesicle 
rupture or ROS induction. Alpha-synuclein aggregates were also shown to induce the 
secretion of exogenously labeled galectin-3.  Grouped together, these experiments help to 
delineate a specific pathway by which cellular pathology may be introduced to cells 
during the propagation of alpha-synuclein and its associated pathology in PD. Gaining an 
understanding of the mechanisms that contribute to the toxicity seen following alpha-
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synuclein aggregate endocytosis may help reveal valuable therapeutic targets for the 
millions of patients who suffer from the horrible symptoms of the LBDs. Downstream 
consequences of cellular exposure to aggregated alpha-synuclein are also elucidated in 
the data studies documented here as well as a possible novel mechanism of cell-to-cell 
transfer.     
 
 
 
Hypothesis 
The structure of alpha-synuclein endows the protein with the ability to perturb 
intracellular vesicles contributing to increased cellular stress and a propensity to 
propagate the cellular stress and downstream pathology.  
 
Specific Aim 1  
Demonstrate that alpha-synuclein can induce endosome/lysosome membrane rupture.  
i)  Define the aggregate species of alpha-synuclein that induces E/L rupture. 
ii)  Determine the relationship between alpha-synuclein aggregate addition and E/L 
rupture. 
iii)  Determine which intracellular vesicle/organelle is being ruptured.  
iv) Determine if active cathepsins are released into the cytosol post E/L rupture.  
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Rationale 
 In its native state alpha-synuclein exists as an unfolded protein but it can adopt a 
variety of conformations and morphologies due to its lack of ordered structure [30, 31]. 
The discovery of missense mutations (A30P, E46K, A53T) [32-35] and structural 
mutations (E37K, E57K) in the alpha-synuclein protein led to intense debate about which 
aggregated form of alpha-synuclein is the most toxic. Previous studies have shown that 
alpha-synuclein can assemble into an oligomer, fibril or filament and that these ordered 
aggregations resemble the pathologic inclusions found in post-mortem tissue of PD 
patients [36-38]. While it is clear that the alpha-synuclein protein carries a heavy 
responsibility for the disease pathology the exact conformation that confers the greatest 
amount of toxicity remains unknown.  
 There has been evidence to show that extracellular alpha-synuclein is endocytosed 
by cells [39, 40]. However, there has been a lack of understanding in determining how 
alpha-synuclein mediates downstream cellular stresses after endocytosis. The course of 
endocytosed alpha-synuclein through the cell and any contributions the protein makes to 
the milieu of cellular stress is not clearly understood currently. One of the goals of this 
project aims to elucidate certain aspects of alpha-synuclein’s interaction with endosomal 
and lysosomal machinery utilizing fluorescent microscopy techniques. Following 
endocytosis it has been shown that alpha-synuclein can access the intracellular cytosol 
[16, 18, 41, 42]. The mechanism of release from an intra-organelle compartment to 
cytosolic compartment is an important transition that is not well understood.  
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 We hypothesize that alpha-synuclein is operating similarly to adenovirus protein 
VI and rupturing the endocytic or lysosomal membrane. The rupture of the lysosomal 
membrane in particular could be disastrous for the cell, given the enzymatic content of 
that organelle.        
 
Specific Aim 2 
Demonstrate that alpha-synuclein can generate reactive oxygen species (ROS) production 
i)  Define the aggregate species of alpha-synuclein that most potently generates 
ROS.  
ii)  Determine the temporal relationship between alpha-synuclein aggregate addition 
and ROS generation. 
iii)  Determine involvement of lysosomal enzymes particularly cathepsins in relation 
to ROS generation.     
 
Rationale 
 Oxidative stress has been well described in the pathology of aging and has been 
linked to neurodegeneration and LBDs [43-45]. We hypothesize that alpha-synuclein can 
generate ROS because of the pivotal role of mitochondria and alpha-synuclein in PD [46, 
47]. Lysosomal rupture would surely release cathepsins which would activate the 
mitochondrial ROS pathway.  
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Specific Aim 3 
Determine if alpha-synuclein is secreted through via a Galectin-3 mediated mechanism. 
i)  Determine the presence of alpha-synuclein in cell culture supernatant.   
ii)  Determine if Galectin-3 is present in cell culture supernatant. 
iii)  Determine if an exosome-like mechanism could be causing the secretion of alpha-
synuclein. 
 
Rationale 
 Neural grafts of fetal midbrain tissue transplanted into the striata of several PD 
patients demonstrated Lewy body pathology not only in the host tissue but in the newly 
grafted tissue as well [48-50]. This has led some to conclude that transfer of alpha-
synuclein from cell to cell is occurring. Alpha-synuclein has been shown to leave cells 
through a variety of mechanisms and various forms of alpha-synuclein have been found 
in the cerebrospinal fluid (CSF), blood, and saliva [51-53]. This indicates that a certain 
percent of alpha-synuclein is in fact being secreted into the extracellular milieu. A recent 
publication by Thurston and colleagues has shown that one of the Galectin (Gal) family 
of proteins, Galectin-8, recognizes ruptured endosomes and targets the ruptured 
endosomes for autophagic degradation [54]. Galectin-3 has been shown to accumulate on 
damaged bacteria-containing vesicles but at this juncture the functional significance of its 
recruitment remains unknown. While it is clear that Galectins are β–galactoside binding 
lectins as aforementioned, and that these peptides are secreted into the extracellular 
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space. Their function in the extracellular space is also unclear. Because of this ambiguity 
and some small preliminary experiments performed in the lab we wish to examine the 
consequences of alpha-synuclein pathology on both the intracellular membranes and 
nuances of cellular stress as detailed in the previous two specific aims. We would be 
remiss if we did not address the possibility of galectin, a protein that can be found 
intracellular and extracellular playing a role in the mechanism of another protein that can 
also be found intracellularly and extracellularly, alpha-synculein.  
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CHAPTER TWO 
REVIEW OF LITERATURE 
 
Parkinson’s disease and other Synucleinopathies 
 Parkinson’s disease (PD), Dementia with Lewy bodies (DLB) and Multiple 
System Atrophy (MSA) are all frequent disorders of an aging population and these 
diseases share a common characteristic: the progressive accumulation of alpha-synuclein 
in the central nervous system and the development of Lewy bodies [55]. Parkinson’s 
disease is undoubtedly the most well-known of these maladies with its first description 
being composed by the English physician Dr. James Parkinson in 1817, Essay on the 
Shaking Palsy [56]. Dr. Parkinson came to describe the condition as paralysis agitans and 
it was finally called Parkinson’s disease by the French physician Jean-Martin Charcot. 
PD affects between 100 to 200 per 100,000 people over the age of 40, with current 
estimates at greater than 1 million people affected in North America alone [5-7]. 
Parkinson disease is uncommon in people younger than 40, and the incidence of the 
disease increases rapidly over the age of 60, with a mean age at diagnosis of 70.5 years 
[4]. In fact, the first and most prominent risk factor for PD is age [57].  The macroscopic 
pathology of PD can be seen clearly; Lewy bodies, which are protein aggregates 
composed of alpha-synuclein as well as other proteins.  These proteinaceous inclusions 
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are found in the substantia nigra pars compacta (SNpc) of PD patients and are the 
histopathological hallmark of these disorders [55]. However, the role of these aggregates 
and alpha-synuclein in PD pathology are not well understood. Gaining a better 
understanding of the cellular and molecular mechanisms responsible for the evolution of 
symptoms seen in PD will be critical for the development of new therapies designed to 
arrest disease progression.  In PD, the role of excessive and misfolded alpha-synuclein 
has been best studied in the SNpc. In line with this data our lab has determined a relevant 
hypothesis and demonstrated some of the molecular mechanisms by which alpha-
synuclein induces a cellular pathology that is spread from cell-to-cell.       
.  
 
Clinical Features of Parkinson’s disease 
PD is the second most prevalent neurodegenerative disorder affecting over 6 
million people worldwide [8]. The three classic motor signs that are seen in Parkinsonism 
are: bradykinesia, rigidity and resting tremor. By the time these motor symptoms have 
appeared it is believed that putamen dopamine uptake is decreased by greater than 35 
percent [58]. The onset of motor symptoms is typically asymmetrical. Presence of two of 
the three cardinal signs combined with a response to the administration of L-Dopa is 
adequate for the clinical diagnosis of PD [59].  James Parkinson termed the disease 
paralysis agitans or “shaking palsy” and the resting tremor is the most visible cue to the 
observer of the neurodegeneration that underlies the clinical condition. Oscillating 
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movements of agonist and antagonist muscles create the tremor that is typically seen in 
PD. While the tremor is one of the first visible signs of the disease it is often most 
pronounced in the distal portions of the extremities, the fingers and hands are the usual 
culprits. As the disease progresses the tremor often decreases in severity while the 
rigidity and bradykinesia become more pronounced [59].  Rigidity can often be most 
clearly seen in the form of gait problems.  PD gait consists of small shuffling steps with a 
lessened armswing and stooped posture [60].  Patients often have difficulty obtaining and 
maintaining their balance, which is part of the underlying etiology of the pronounced 
gait.  Bradykinesia, which is defined as a slowness of movement can lead to akinesia or a 
complete lack of movement as PD progresses.  
While the motor syndrome is what PD is infamous for, there are a range of non-
motor symptoms as well. One of the most common symptoms that overlaps with DLB 
and Alzheimer’s disease (AD) is dementia.  Dementia develops in 20-40% of PD 
cases[61]. Yet, the cognitive deficits are not exactly the same as what is typically seen in 
dementia cases, it usually includes executive impairment, episodic memory impairment, 
visuospatial dysfunction and impaired verbal fluency[62]. It has been suggested that there 
is an important interplay between the motor impairments commonly seen in PD and the 
cognitive deficits. Deep brain stimulation (DBS) does not ameliorate or alleviate the 
cognitive, psychiatric or verbal dysfunction seen in patients with PD.       
      
Current Treatment for Parkinson’s disease 
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 Currently no cure exists for PD and all that can be offered to patients is 
symptomatic management which can be done with close monitoring, precise medication 
adjustments, education, exercise and sometimes surgery.  Once a diagnosis of PD has 
been made, the choice to start medical treatment depends on the severity of the symptoms 
that patient faces.  Of paramount importance is the patient’s ability to perform activities 
of daily living (ADLs).  There are currently 5 classifications of drug that may be used to 
treat the symptoms of  PD: levodopa, dopamine agonists, anticholinergics, monoamine 
oxidase B (MAO-B) inhibitors, and catechol-O-methyltransferase (COMT) inhibitors 
[63].  All work at the neurotransmitter level in an attempt to replenish the missing 
dopamine.  Levodopa is the most commonly used medication for the treatment of the 
motor symptoms of PD. It is often combined with carbidopa to prevent peripheral 
metabolism of levodopa and allow more levodopa to cross the blood brain barrier (BBB).  
In the United States formulations of carbidopa-levodopa are marketed under the name, 
Sinemet®.  Correct dosing of Sinemet® is crucial, as the lowest dose possible should be 
used to control motor symptoms.  The reasons for this are the dyskinesias associated with 
prolonged supplemental exposure to levodopa.  Long-term exposure of five to ten years 
results in these abnormal involuntary movements for at least fifty percent of the patients 
taking levodopa [63, 64].  There are currently no treatments to halt or slow the 
progression of PD.   
 The most frequently performed surgery for the treatment of advanced PD is DBS 
[65].  Excessive STN excitation of the internal globus pallidus and excessive GP 
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inhibition of the thalamus are two of the downstream consequences of nigral/dopamine 
deficiency. DBS addresses these inhibitory factors by electrically and reversibly 
interfering with these inhibitory signals. These, in turn, cause reduced thalamocortical 
activity, which is believed to mediate the symptoms of akinesia and rigidity.         
 
Parkinson’s disease and Basal Ganglia Circuitry 
 While PD’s cardinal symptoms affect motor control these deficits originate from 
the basal ganglia (BG). The BG is functionally as well as anatomically related set of 
nuclei that include the caudate and putamen (together the caudate and putamen are called 
the striatum), Globus Pallidus pars interna (GPi), Globus Pallidus pars externa (GPe), 
substantia nigra pars reticulate (SNpr), substantia nigra pars compacta (SNpc), and the 
Subthalamic Nucleus (STN). These nuclei are the principle components of the 
extrapyramidal motor system which plays a role in the initiation of voluntary movements, 
facilitation of some motion suppression and feedback from evolving motions [59]. The 
majority of the afferent projections into the BG comes from the cerebral cortex and goes 
to the striatum [66]. Efferent projections leave the BG from the GPi and SNpr and 
activate the ventral anterior and ventral lateral thalamic nuclei (Figure #1). The ventral 
lateral thalamic nuclei has a main function of movement execution and projects to the 
primary motor cortex in the precentral gyrus of the frontal lobe, while the ventral anterior 
thalamic nuclei has a main function of movement planning and projects to the premotor 
and supplementary motor cortex of the frontal lobe [66]. 
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 The BG forms a complex network of circuits. However, there are two primary 
pathways through the BG circuitry: the “direct” and the “indirect” pathway [66]. In the 
“direct” pathway begins with putamen projections to the GPi as well as the SNpr, which 
are both output sources of the BG [66]. The “direct” pathway contains D1 dopamine 
receptors and co-expresses the peptides Substance P and Dynorphin. However, the main 
neurotransmitter used in the pathway is γ–aminobutyric acid (GABA), an inhibitory 
neurotransmitter and since the direct pathway is an inhibitory pathway when activated the 
reduction of inhibitory effects leads to a facilitation of movement. The “indirect” 
pathway links the putamen with the GPe and STN [66]. D2 dopaminergic receptors are 
used in the “indirect” pathway as well as the peptide enkephalin [59]. Activation of this 
pathway leads to a suppression of movement. Due to the presence of D1 and D2 
dopamine receptors in the “direct and “indirect” pathway it is clear that dopamine can 
exert a dichotomous effect on each pathway: activating D1 receptors in the direct 
pathway and inhibiting D2 receptors in the indirect pathway. Yet, these two contrasting 
pathways when activated by dopamine come to facilitate movement.  
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 Figure #1: Basal Ganglia Circuitry. Image by Mikael Haggstrom from Wikipedia 
commons used under Creative Commons Share 3.0.  
 
 A progressive loss of dopamine has been well established as one of the key 
outcomes of PD (Figure #2). This deficiency reduces inhibition of the “indirect” pathway 
and diminishes excitation of the “direct” pathway which creates an overall increase of 
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inhibition in the motor system (Figure #2) [59].  These “direct” and “indirect” pathway 
models provide a good framework for PD, but unfortunately they do not provide any 
insight into the etiology and pathophysiology of PD.         
 
 
Figure #2: Basal Ganglia Circuitry in Parkinson’s disease. Image by Mikael Haggstrom 
from Wikipedia commons used under Creative Commons Share 3.0. 
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Selective Neuronal Vulnerability in Parkinson’s disease 
 The underlying characteristics of these specific SNpc neurons that allow them to 
be specifically vulnerable remains a fiercely contested question. Many of the risk factors 
as well as environmental factors involved in the etiology of PD are either ubiquitously 
expressed or systemically exposed.  What is distinctive about the cellular milieu and 
environment created by the SNpc that makes the neurons in that area so vulnerable?  
SNpc neurons are in fact physiologically different from the vast majority of other neurons 
present in the brain.  Their distinction from other neurons originates from the SNpc’s 
ability to autonomously generate action potentials (AP) without any synaptic input [67].  
APs are generated around 2-4 hertz and this rhythmic pacemaking activity is thought to 
help maintain high intracellular levels of dopamine [68].  This is in stark contrast to the 
electrophysiology driving most neurons, which consists of monovalent cation channels. 
SNpc neurons allow calcium to enter the cytoplasm through L-type calcium channels that 
have a distinct Cav1.3 poreforming subunit encoded by Cacna1d  [69, 70].  The Cav1.3 
subunit alters normal L-type calcium channel behavior by forcing the channel open 
during hyperpolarization which helps the cell reach threshold potential [69].   
 
The sustained engagement of Cav1.3 calcium channels during pacemaking 
comes at an obvious metabolic cost to SNpc neurons. Because of its 
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involvement in cellular processes ranging from the regulation of enzyme 
activity to programmed cell death, calcium is under very tight homeostatic 
control, with a cytosolic set point near 100 nM; that is 10,000 times lower 
than the concentration of calcium in the extracellular space. Calcium 
entering neurons is rapidly sequestered into the sarcoplasmic reticulum or 
pumped back across the steep plasma membrane concentration gradient; 
this process requires energy stored in ATP or in ion gradients that are 
maintained with ATP-dependent pumps (Figure# 3). In most neurons, 
calcium channel opening is a rare event, occurring primarily during very 
brief action potentials. [71]   
 
The presence of this Cav1.3 subunit makes SNpC neurons substantially more vulnerable 
to any other stress, particularly any additional metabolic stressors as the metabolic 
machinery must overly exert itself in order to maintain calcium homeostasis.  
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Figure # 3: Calcium transport in SNpC neurons. [71] 
 
 
Parkinson’s disease and alpha-synuclein 
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PD is characterized by a progressive loss of specific dopaminergic neurons in the 
BG as well as the presence of Lewy bodies (LB) and Lewy neurites (LN) [8].  LBs are 
intracytoplasmic aggregations of the protein alpha-synuclein (Figure #4) which can also 
be found intra-axonally and are called Lewy neurites (LN) [72-75].  These LBs and LNs 
were found to localize with alpha-synuclein staining in both sporadic and familial cases 
of PD [73, 75].  In many cases, LNs are found to be present without LBs, suggesting that 
LN formation may occur prior to LB formation [55].  DLB and MSA are two other 
synucleinopathies that have been found to contain neuronal as well as glial cytoplasmic 
inclusions that contain alpha-synuclein immunoreactivity [55].  Alpha-synuclein 
immunoreactivity is not visible in neuronal cells under normal conditions [55]. Friederich 
H. Lewy was the first to describe strange cytoplasmic inclusions found in the nucleus 
basalis of Meynert and the dorsal vagal nucleus in PD patients over one hundred years 
ago [76].   
 
LBs composition has been a key area of research and it was uncovered that they 
are composed of filamentous structures [77, 78]. These filamentous structures resemble 
neurofilament (NF) but are thicker with a complete lack of side-arms [55].  LBs can be 
found through the central nervous system (CNS): hypothalamus, nucleus basalis of 
Meynert, substantia nigra, locus ceruleus, dorsal raphe nucleus, dorsal vagal nucleus, 
intermediolateral nucleus of the spinal cord (SPC) [79, 80].  Yet documented instances of 
LBs are not limited to the CNS, with recent papers showing the presence of LBs in the 
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sympathetic ganglia, the enteric nervous system, adrenal medulla, and the cardiac plexus 
[10, 55, 81-83].  This distribution of LBs to a myriad of different places in the nervous 
system underscores the variety of symptoms that can be present in a PD patient as well as 
the dramatic variability seen in the symptoms of the other LBDs.      
 
Figure #4: Lewy Body. Image from Wakabayashi 2007, “The Lewy Body In 
Parkinson’s disease: molecules implicated in the formation and degradation of alpha-
synuclein aggregates”. Neuropathology 2007; 27, 494–506.  
 
22 
 
 
 
LB’s linked alpha-synuclein to PD.  However, alpha-synuclein is a 
multifunctional protein that has been linked to numerous cellular processes [84].  Another 
integral link between alpha-synuclein and PD was unearthed in 1997 when 
Polymeropoulos and colleagues found a point mutation (A53T) in alpha-synuclein that 
was linked to an early-onset autosomal dominant genetic form of PD [32]. While the 
mutation was only present in a small population of Italian and Greek families it had a 
high penetrance leading to the significance of the finding [32]. In the same year, full 
length alpha-synuclein was found to be the major component in the proteinaceous 
aggregates known as LBs found in autopsy tissue from sporadic PD patients [73, 75].  
Two other point mutations have since been found (A30P and E46K) further strengthening 
the link between alpha-synuclein and PD [85, 86].  Gene dosing of the alpha-synuclein 
gene has been shown to be associated with PD in rare duplication or multiplication events 
[87, 88].  The genetic link between alpha-synuclein and PD is clear for familial PD and 
recently genome-wide association studies (GWAS) have shown that sequence variants in 
SNCA, the gene the encodes alpha-synuclein, are strongly associated with the sporadic 
form of PD [89, 90].  Put together these studies provide strong evidence that the protein 
alpha-synuclein plays a key role in the pathophysiology of PD.  
 
Alpha-synuclein structure 
Alpha-synuclein is 140 amino acids long, hydrophilic affinity for membranes, 
natively unfolded protein that is present in large numbers of adult human neurons. It was 
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originally found in Torpedo californica [91].  Being found to localize in two distinct 
cellular locations: the nuclear envelope and the presynapse, the protein was given the 
moniker “synuclein” [8, 84]. While alpha-synuclein is found only in mammalian species 
with a significant amount of conservation between species sequences, synucleinopathy 
only occurs in humans [84].  There exists a synuclein family of proteins: alpha, beta and 
gamma and these proteins share a common amino terminal sequence [8, 84].  The alpha-
synuclein gene maps to chromosome 4q21.3-q22 [92, 93].  Alternative splicing generates 
three separate alpha-synuclein isoforms for humans: 140 amino acids, 126 amino acids 
and 112 amino acids [16]. The 140 amino acid isoform is the full length transcript and the 
most abundant [94].  The 126 amino acid isoform is generated due to an in-frame deletion 
of exon 3, while the 112 amino acid variant is caused by a in-frame deletion of exon 5 
[95].  Alpha-synuclein is so abundant that it has been estimated to make up one percent 
of the total protein in soluble cytosolic brain fractions [96]. Knockout of the alpha-
synuclein gene generates viable offspring which have small increases in dopamine 
release and a reordering of the vesicular synaptic pool [97, 98].  It is believed that this is a 
result of an alteration in synaptic vesicle exocytosis or endocytosis because either could 
lead to an upregulation in neurotransmisstion. In-vivo overexpression of alpha-synuclein 
has been correlated with a small decrease in secretion of neurotransmitter, most notably 
dopamine [39, 99]. In-vitro and in-vivo evidence has indicated that both reduction as well 
as overexpression of alpha-synuclein can induce neurodegeneration [100]. 
Overexpression of alpha-synuclein leads to an increase in protein aggregates [9].    
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The molecular mass of alpha-synuclein, as predicted by matrix-assisted laser 
desorption/ionization time of flight (MALDI-TOF) is 14,463 very close to the mass 
predicted from the amino acid sequence. However its large Stokes radius (34 Ẫ) indicates 
that the native protein is in an elongated form [84].  It has been well established that 
alpha-synuclein has a natively unfolded structure.  This unfolded structure is a result of 
three distinct regions of the synuclein transcript: 1) N-terminal region, 2) central region 
and 3) C-terminal region (Figure #5).  Residues 1-60 constitute the N-terminal region 
which includes a seven time imperfectly recurring 11 residue sequence that has a highly 
conserved hexamer (KTKEGV) motif [21, 84, 95, 101].  The highly repetitive nature of 
this sequence gives rise to the amphipathic alpha-helical structure of alpha-synuclein. It is 
this structure, which is akin to the lipid-binding domain of apolipoproteins that allows 
substantial interaction with lipid membranes [102].  It is worth noting that within this N-
terminal region lie the three specific mutations that give rise to some cases of familial PD 
(A30P, E46K, A54T).  The central region, consists of residues 61-95 and within that 
stretch of amino acids is the non-Aβ component (NAC) region [93, 103, 104]. The NAC 
sequence is a highly hydrophobic region which is prone to aggregation and in fact 
necessary for alpha-synuclein aggregation [103].  Residues 96-140 compromise the C-
terminal region which contains cation binding sites and is characterized by a high amount 
of acidic proline residues [8, 84].  
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Figure #5: Schematic of alpha-synuclein transcript. Belluci et al 2012. 
 
 
Alpha-synuclein Lipid and Membrane Interaction 
When alpha-synuclein is in its monomeric state it exists in a flux between being 
free in the cytoplasm and being bound to lipid membranes. While unbound in aqueous 
solution alpha-synuclein is mostly a random coil but when exposed to lipid membranes it 
quickly adopts an alpha-helical secondary structure [105].  The amino acid sequence 
which makes up the N-terminal region as well as the localization of alpha-synuclein at 
the presynapse indicates that it is a protein built to play a role in the membrane.  
Specifically, the alignment of the nonpolar hydrophobic residues into the lipid bilayer 
and the polar hydrophlic residues in the opposite direction toward the aqeous cytoplasm 
allows alpha-synuclein a partial insertion into the lipid bilayer without the traditional 
transmembrane domain. This partial insertion is also secured in the lipid bilayer from 
lysine residues that are laterally aligned and allow further interaction with the negatively 
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charged phospholipid head groups [18, 31, 106] (Figure #6). Whilst binding to the 
membrane, the N-terminal portion of alpha-synuclein folds into one of two possible 
amphipathic alpha-helical conformations [106]. Conformation can be: uninterrupted N-
terminal alpha-helix or two broken anti-parallel alpha-helices with the break between 
amino acids 44 and 45 [107].  Conformation depends on the underlying membrane 
curvature: the broken helix is formed on lipid surfaces with a high degree of curvature, 
while the uinterrupted helix is formed on less curved lipid surfaces [106, 108].  The N-
terminal hydrophobic residues reside in the outer leaflet of the membrane, while the C 
terminus remains unfolded in both conformations [109].  These characteristics indicate 
that alpha-synuclein possesses the ability to be a membrane curvature sensor [109].  In 
addition, recent experiments using synthetic liposomes have shown that alpha-synuclein 
can also generate membrane curvature. [21, 110]  
 
While this static model is well accepted it does not take into account the flux of 
alpha-synuclein between membrane-bound and free in the cytoplasm. Some evidence 
exists to suggest that some cytoplasmic machinery participates in the dynamic 
relationship between alpha-synuclein and the membrane. When artificial synaptic 
vesicles are bound to alpha-synuclein and cross-linked these assemblies become 
stabilized, suggesting that other proteins help to facilitate this interaction between lipid 
bilayer and alpha-synuclein [111].  The Tandon group from Toronto has very recently 
shown that, “anti-Rab3a antibodies strongly inhibited alpha-synuclein binding to 
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synaptosomal membranes” [100].  The GTP form of Rab3a co-immunoprecipitated with 
alpha-synuclein indicating that Rab3a machinery plays a role in the dynamic relationship 
between n alpha-synuclein and the phospholipid membrane [100].  Yet, the implication of 
this relationship and neurodegeneration remains to be elucidated.             
 
 
 
Figure #6: Structure of alpha-synuclein revealing its amphipathic nature. Image 
procured from NCBI Structure, screen capture of Cn3D viewer 4.3.  
 
Aggregation of Alpha-synuclein 
Different conformational states and aggregated morphologies are possible for 
alpha-synuclein due to its intrinsically unfolded nature.  These morphologies include: 
small aggregates, oligomers/multimers, protofibrils, β–sheet fibrils and α–helical 
structure when bound to membranes.  Oligomer formation precedes fibril formation and 
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these oligormers have a wide variety of morphologies which depend on the incubation 
conditions [36].  Of the family of synucleins the alpha-synuclein protein is the most 
aggregation prone compared to β-synuclein and γ-synuclein [30].  
 
Sequence analysis for the aggregation of alpha-synuclein has been an area of 
intense interest. The hydrophobic core of the protein, 35 amino acid NAC region, which 
was originally isolated from the brains of AD patients [104] plays an integral role in the 
aggregation process. While this central hydrophobic region facilitates aggregation the C-
terminus of the protein inhibits aggregation and in fact when the C-terminus is truncated 
the abbreviated protein is more aggregation prone than the full-length protein [36]. Post-
translational modifications of alpha-synuclein are numerous and the phosphorylation of 
Ser129 has been shown to increase the formation of fibrils [112].  When alpha-synuclein 
is bound to a membrane it has been shown to have an increased propensity to aggregate 
[113].   
 
Currently, there is much debate as to which aggregate species is the most toxic.  It 
is clear that the self-association tendencies of alpha-synuclein play a fundamental role in 
the  neuronal dysfunction that is seen in PD and other synucleinopathies [114].  Some 
have suggested that the smaller oligomeric species are pathogenic while others have 
evidence that suggests the larger fibrillar species are pathogenic. Studying the 
conformational state of alpha-synuclein is notoriously difficult due to its inherently 
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unstructured nature and its ability to adopt a variety of conformations depending on 
experimental conditions [114].  Oligomeric species of alpha-synuclein are initially 
formed and considered to be relatively soluble [36].  Once the fibrillar state has been 
reached the structures become insoluble [36]. Insoluble fibrils have been detected in the 
brains of patients with PD via electron microscopy (EM) [73]. These filaments fall into 
two separate categories: linear as well as annular/circular and have a range of sizes that 
span from 50-700 nanometers (nm) [73].  Even oligomeric forms can attain a spherical 
morphology in the presence of divalent cations and these spherical oligomers have been 
shown to disrupt lipid bilayers [115]. Lipid bilayer disruption allows for an increase in 
cell permeability. Alpha-synuclein in the protofibrillar state can also form pore-like 
assemblies and these can act as an ion channels which may help explain some of the 
underlying vulnerability for these neurons to neurodegeneration (Figure #3) [116].   
 
Cell to Cell transfer of Alpha-synuclein 
Ten years ago Heiko Braak developed a staging method to describe the brain 
pathology seen in PD [117].  This staging method details the spatial and temporal spread 
of alpha-synuclein pathology of PD.  In particular, the Braak method describes the 
presence of LB pathology (Figure #5) and correlation with PD symptom severity (Figure 
#7).  Stage 1 describes LB and LN presence in the olfactory bulb and the vagus nerve 
[117, 118]. Stage 2 the pathology spreads toward the brainstem with involvement of the 
medulla oblongata specifically [117, 118].  Patients in these early stages do not exhibit 
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the motor symptoms typically associated with PD but may have some of the non-motor 
symptoms (anosmia, constipation). It is unclear if patients who have pathology at these 
stages are bound to progress and develop PD later in life.  LB and LN pathology are 
found in the substantia nigra and amygdale in stage 3 [117, 118].  It is not until this stage 
that motor symptoms are expected to develop.  Stage 4 sees the presence of LB and LN in 
the forebrain and cerebral cortex.  Finally in stages 5 and 6 the pathology spreads toward 
the prefrontal cortex where its presence can contribute to the dementia that can be 
frequently found within the PD and DLB populations [117, 118].  From this correlative 
staging Braak hypothesized that there is a pathologic agent responsible for this type of 
gradual, infectious-like spread. Alpha-syunclein was quickly assigned the role of 
pathologic agent.  Several cellular processes must be possible if alpha-synuclein can act 
as this prion-like pathologic agent. These cellular processes include: cellular release, 
cellular uptake, and most importantly the ability to “seed” pathology in a new cell.  
In PD patients alpha-synuclein has been detected in the CSF as well as the plasma 
[51] suggesting that in the disease state affected cells may release alpha-synuclein even 
though it does not contain a secretory peptide sequence. Extracellular alpha-synuclein has 
also been found in the culture medium of human neuroblastoma cells as well as rat 
primary cortical neurons [119, 120].  Alpha-synuclein is secreted by non-classical 
exocytosis as it does not have a secretory peptide sequence.  Following secretion from an 
initially affected cell alpha-synuclein must make its way to another cell for uptake.  
Neuronal cells in culture have demonstrated an endocytosis-dependent ability to take up 
31 
 
 
 
alpha-synuclein in both the monomeric form as well as the oligomeric and fibrillar forms 
[121].  Once transferred to another cell, alpha-synuclein needs to “seed” the endogenous 
intracellular alpha-synuclein. Recent experiments have shown this seeding pathology in a 
striking way. Desplats et al grafted murine neuronal progenitor cells into the 
hippocampus of mice that were expressing human alpha-synuclein and when the grafts 
were examined at one week post-transplant there was human alpha-synuclein staining 
present [122].  At 4 weeks, some of the graft contained alpha-synuclein aggregates which 
contained human alpha-synuclein.  The Kordower group has shown that transplanted 
human fetal mesencephalic tissue into the SNpc of PD patients has resulted in accelerated 
pathological change in the neuronal cells found in the graft [48, 49]. Recently the 
Virginia Lee lab used mouse alpha-synuclein aggregates injected into the dorsal striatum 
and observed LB-like structures present in the striatum as well as other areas 
interconnected with the striatum [123].  There was a loss of dopamine and concomitant 
motor symptoms in these mice as well [123].  A caveat to this transfer quality has been 
uncovered; the recipient cells must express alpha-synuclein. When alpha-synuclein 
aggregates were injected into alpha-synuclein knockout mice there was a noticeable lack 
of aggregate propagation, confirming that endogenous alpha-synuclein expression is 
absolutely required for recruitment in this pathogenic process [124].  While the Braak 
hypothesis is still controversial, there seems to be a boon of evidence that describe the 
capacity of alpha-synuclein to act in a prion-like fashion.  
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Figure #7: Schematic of spatial and temporal spread of LB per the Braak hypothesis. 
Adopted from [125]  
 
Alpha-synuclein exhibits significant similarities to adenovirus protein VI 
The literature exploring the molecular biology and pathological potential of alpha-
synuclein is remarkably similar to studies exploring the mechanisms and pathological 
consequences of infection by non-enveloped viruses, specifically adenovirus. Because it 
lacks a membrane, adenovirus cannot rely on the fusion of viral and target cell 
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membranes to deliver its capsid and genome into the target cell cytoplasm. Instead, 
adenovirus utilizes a viral protein named protein VI (pVI) to achieve this goal. Following 
the endocytosis of adenovirus, pVI is released from the viral core and mediates the 
mechanical disruption of the endosomal/lysosomal (E/L) membrane [22]. Molecular 
studies of pVI have demonstrated that this protein is an amphipathic alpha-helix that 
possesses the ability to induce membrane curvature of endosomes and other experimental 
liposomes [126].  Notably, alpha-synuclein is also known to form an amphipathic alpha-
helix in the presence of membranes (Figure #4) [18, 31, 106] and can induce membrane 
curvature  [41, 42]. In fact, both pVI and alpha-synuclein induce a nearly identical 
disruption of artificial liposomes (Figure #8). Critically, the Wiethoff lab has 
demonstrated that disruption of endosome/lysosome (E/L) membranes by pVI results in 
an increase in mitochondrial ROS in target cells [27]. Cathepsin release from ruptured 
E/Ls mediates this effect, as ROS generation is inhibited by the cathepsin B inhibitor CA-
074 [27, 127, 128]. The idea that alpha-synuclein may similarly rupture E/Ls, and thereby 
induce similar consequences, is the foundation of this proposal. 
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Figure #8: Disruption of experimental liposomes using aggregated alpha-
synuclein in A as demonstrated by Varkey et al [42].  and adenovirus protein VI in B as 
demonstrated by Maier et al [126]. 
 
Significance 
PD is the second most common neurodegenerative disease with an anticipated 
spike in patients due to the increasing longevity of the overall global population from the 
recent medical advancements made in other fields [4-7, 74].  Recent advances have made 
it clear that the protein alpha-synuclein plays a key role in the pathogenesis of this 
disease [3, 8, 9].  The structure of alpha-synuclein, an amphipathic alpha-helix, is an 
integral part of its ability to bind membranes and the similarity to adenovirus protein VI 
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is striking.  The ability of alpha-synuclein to be secreted, taken up and seed pathology in 
cultured neurons as well as animal models lends authenticity to the prion-like hypothesis 
of alpha-synuclein propagation.  Yet the exact mechanisms by which alpha-synuclein 
escapes from the endosome/lysosome remain largely unexplored. Thus the process of 
how an endocytosed protein becomes an intracellular protein has been the focus of this 
research.  Given the importance of alpha-synuclein and how its molecular escape 
mechanism remains largely unexplored warrants deeper investigation. 
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CHAPTER THREE 
ALPHA-SYNUCLEIN AGGREGATES CAN INDUCE LYSOSOMAL 
MEMBRANE RUPTURE AND RELEASE ACTIVE CATHEPSIN B  
 
Abstract 
PD as well as a host of other synucleinopathies have implicated a clear 
pathological role for alpha-synuclein. Alpha-synuclein has been shown to introduce an 
intracellular pathology that can be spread from cell-to-cell. However, the molecular 
mechanism by which alpha-synunclein induces this pathology is not well understood.  
Just as adenovirus ruptures intracellular vesicles we believe that alpha-synuclein operates 
similarly.  In order to pursue this line of inquiry we had to categorize the effects on cells 
using various aggregate preparations.  Aggregates were created using in-vitro purified 
recombinant protein subjected to incubations of varying length. Using a novel 
microscopy assay we were able to determine that intracellular vesicular rupture was 
occurring. Given the power of this assay we were able to determine which type of 
intracellular vesicle was being ruptured and the temporal relationship between the 
addition of alpha-synuclein aggregates and vesicular rupture.  Due to the indication that 
the intracellular vesicle being ruptured was in fact a lysosome, and because lysosomes are 
replete with catalytic enzymes we endeavored to determine if the cathepsins being spilled 
into the cytosol were active.  Given the important role in disease propagation, 
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progression, dysfunction and neurodegeneration, understanding the cellular mechanism 
of alpha-synuclein aggregates is of significant importance.  In summary, our study 
demonstrates that aggregates induce the most rupture from the neuronal cells as soon as 
24 hours after aggregate addition, and it is these aggregates that induce the rupture of 
lysosomes and the subsequent release of active cathepsin B.  
 
Introduction 
Numerous bodies of literature indicate that alpha-synuclein is clearly involved in 
the etiology of PD [8, 35, 55, 87, 93, 129-131]. Specifically, that neuronal pathology and 
cellular stress are increased in PD [8, 132-136]. In vivo and in vitro studies further 
demonstrate that acute exposure to alpha-synuclein aggregates lead to increased 
mitochondrial stress, endoplasmic reticulum (ER) stress, and problems associated with 
intracellular protein degradation machinery. Closely related in structure and membrane 
affinity to adenovirus protein VI, alpha-synuclein is a protein that clearly has the 
possibility to rupture intracellular vesicular membranes.  Despite the overwhelming 
amount of evidence indicating the structural similarity of these two proteins, only a small 
number of studies have examined the effects of alpha-synuclein on membranes, 
specifically intracellular vesicle membranes [16, 41, 42, 100, 106, 107, 109, 115]. 
 
In addition to the toxic oligomeric form of alpha-synuclein that is retained in 
neurons, a significant amount of alpha-synuclein is released from cells and can be taken 
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up via endocytosis into recipient cells [122, 137].  Despite knowing how cells take up 
alpha-synuclein aggregates, not much is known about these aggregates once they have 
been internalized.  Due to their ability to bind and bend membranes, [16, 41, 42, 100, 
105-107, 109] as well as their presence in the cytosol, it has been hypothesized that 
intracellular vesicle rupture occurs.  Fortunately, an assay in the field of virology has 
been developed for the specific purpose of monitoring intracellular vesicle membrane 
integrity [22, 27, 126-128].  This assay was developed exploiting the biological 
properties of a protein called galectin-3 (gal-3).  Very recently, Paz et al was able to 
identify gal-3 as a cytosolic protein that could act as a marker for ruptured phagosome 
membranes [138].  Gal-3 is a member of the galectin family of proteins, which all 
members contain a consensus sequence in its carbohydrate recognition domain (CRD) 
[139-141].  This consensus sequence has a distinct affinity for β–galactoside containing 
glycoconjugates [139-141].  N-linked glycans, a type of β–galactoside containing 
glycoconjugates, are found on the exterior leaflet of the plasma membrane as well as the 
interior leaflet of any vacuole/vesicle that is involved in the endocytic process.  
Immediately following membrane disruption the cytosolic gal-3 is recruited to the area 
where the N-linked glycans are exposed from the interior vacuole surface following lysis 
[138].  Immunofluorescence microscopy (IFA) can be used to monitor membrane rupture 
when gal-3 is fluorescently tagged.  In the absence of rupture gal-3 staining appears 
diffuse in the cytosol, whereas the fluorescent signal appears punctuate after being 
recruited to a ruptured membrane (Figure #9) [138].  Maier et al recently used this 
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technique to demonstrate that adenovirus type 5 (Ad5) is able to mechanically disrupt 
endosomal membranes to gain access to the cytosol [126].   Galectin-8 and galectin-9 
have also been shown to be recruited to ruptured membranes [54, 142].          
 
Figure #9: Schematic of galectin-3 localization with intact vesicular membranes 
and with ruptured vesicular membranes. [143] 
 
Currently, the literature addressing intracellular membrane rupture of alpha-
synuclein is sparse.  It has been shown that uptake of alpha-synuclein aggregates is 
attenuated by low temperature and inhibitors of dynamin [120, 144].  Alpha-synuclein 
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has also been shown to colocalize with Rab5a and Rab7, with dominant negative Rab5a 
models showing reduced endocytosis of alpha-synuclein [122].  Also, when cells are 
treated with trypsin, removing endocytic receptor proteins, the uptake of alpha-syunclein 
is inhibited [145].  In fact a recent review by the Brundin group asks “how does alpha-
synuclein leave the endosome to access the cytosol?”[146] . Meanwhile, the Thurston 
group has shown that gal-3, gal-8 and gal-9 are recruited to LAMP1 positive vesicles, 
indicating that Salmonella Typhimurium ruptures the lysosomal membrane [54].  Gal-3 
can be used as a sensor for E/L rupture and further investigation of which intracellular 
vesicle is ruptured will be helpful.  Rupture of the lysosome will result in the possible 
activation of multiple downstream pathways.  Cahepsins are tightly regulated cellular 
proteins which are generated as zymogens that are activated once a low pH has been 
reached in the endosomal/lysosomal compartment.  The release of cathepsin from these 
compartments post-activation would lead to unregulated intracellular damage due to the 
cleavage of cellular proteins creating an impairment of cellular functions [147].  
Depending on the degree of cathepsin dysregulation, effects can range from generation of 
ROS to the induction of apoptosis, both of which are well established aspects of PD 
pathology [27, 148].       
 
To explore the impact of aggregated alpha-synuclein on intracellular vesicle 
membrane integrity, our study utilized two neuronal cell lines: N27, a rat dopaminergic 
cell line; and SH-SY5Y, a human neuroblastoma cell line. Both cell lines have been 
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stably transduced to express mcherry labeled galectin-3 (chgal-3) in order to evaluate the 
spatial and temporal characteristics of alpha-synuclein aggregates on intracellular vesicle 
membrane integrity.  Using differentiated neuronal cell lines, our study models a scenario 
in which the neurons are challenged with a variety of different sized aggregated alpha-
synuclein.  We also sought to determine if there is a temporal relationship between 
vesicle rupture and aggregate addition as well as any downstream consequences of that 
rupture.  Herein, we are able to show that exposure to alpha-synuclein aggregates results 
in a membrane perturbation of both cell lines at twenty-four hours of exposure to 
aggregates. Moreover, our data suggests that alpha-synuclein aggregates have more 
profound effects on late-stage lysosomes than endosomes. Lastly, we demonstrate that 
cathepsin B is released from these late-stage lysosomes. 
 
Materials and Methods 
 
Cell Lines 
The human neuroblastoma cell line, SH-SY5Y was obtained from the American 
Type Culture Collection (ATCC). The rat dopaminergic neuronal cell line was a kind gift 
from Dr. Anumantha Kanthasamy.  SH-SY5Y cells were maintained and differentiated 
with 50 mM all L–trans Retinoic acid every 48–72 hours in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS)(Hyclone) and 100 
IU/mL penicillin, 100 µg/mL streptomycin and 10 µg/mL ciprofloxacin. The rat 
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dopaminergic cell line N27 was cultured in RPMI media supplemented with 10% fetal 
bovine serum (FBS)(Hyclone) and 100 IU/mL penicillin, 100 µg/mL streptomycin and 
10 µg/mL ciprofloxacin. Cells were maintained in a 37°C incubator with 5% CO2.  The 
mCherry-gal3 plasmid was a generous gift from Dr. Christopher Wiethoff.  Retroviral 
vectors were generated utilizing transfection of 293T cells with the packaging plasmids 
vesicular stomatitis virus glycoprotein (VSV-g), pCigB and mCherrygal-3.  Transfections 
were performed using polyethylenimine (PEI) (molecular weight, 25,000; Polysciences) 
as previously described [149].  Supernatants containing these recombinant retroviral 
vectors were collected 48 hours post-transfection and used to transduce SH-SY5Y and 
N27 cells. Positive transductants were selected with Geneticin/G418. 
 
Alpha-synclein 
Full length alpha-synuclein and the E46K missense mutant alpha-synuclein were 
purchased (rPeptide) and the lyophilized protein was rehydrated in PBS with 100 mM 
NaCl immediately upon arrival to a concentration of 1 mg/ml and was aliquoted and 
stored at 
-
80°C. In order to generate aggregates, alpha-synuclein was incubated for 3 days 
at 37°C under constant agitation at 300 revolutions per minute (rpm) followed by storage 
at 
-
80°C. Aggregates were added at a concentration of 3µg/ml per the protocol provided 
by Volpicelli-Daley [150].  Aggregates were fluorescently labeled with Dylight® 488 N-
hydroxysuccinimide (NHS)-ester fluorophores (Thermo Scientific), according to the 
manufacturer's protocol prior to use.  Briefly, the aggregates were dialyzed into a sodium-
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phosphate buffer with pH 8.0. After dialysis the aggregates were labeled with the 
Dylight® 488 for thirty minutes.  The reaction was quenched using 40mM Tris and 
dialyzed again.  These aggregates were then stored at 
-
20°C.  
  
Coomassie 
Samples were run on a native 10% polyacrylamide gel. Gel was fixed using 
colloidal coomassie fixative (45% methanol and 10% acetic acid) for 1 hour. Gel was 
then placed in Coomassie Brilliant Blue G-250 (MP Pharmaceuticals) overnight at room 
temperature. The following morning the gel was imaged using a BioRad ChemiDoc XRS 
imaging system (BioRad). 
 
Western Blot Analysis 
Purified proteins were separated via sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, (SDS-PAGE), proteins were transferred to nitrocellulose membranes and 
detected by incubation with the primary antibody. The H3C monoclonal antibody 
developed by Julia George was obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD and maintained by The University of 
Iowa, Department of Biology, Iowa City, IA 52242. Secondary antibody conjugated to 
HRP (Thermo Scientific) was used where necessary, and antibody complexes were 
detected using SuperSignal West Femto chemiluminescent substrate (Thermo Scientific). 
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Chemiluminescence was measured using a BioRad ChemiDoc XRS imaging system 
(BioRad). 
 
Glutaraldehyde Cross-linking 
Equivalent amounts of aggregated alpha-synuclein and monomeric alpha-
synuclein were incubated with 0, 1, and 2 µM glutaraldehyde for 15 minutes at room 
temperature. 1 M glycine was added after 15 minutes to saturate the glutaraldehyde. 2× 
SDS sample buffer was added and the mixture was boiled for 5 min at 100°C. The 
samples were then subjected to SDS-PAGE using 4%–15% Tris–HCl gradient gels 
(Ready Gels, BioRad) and subsequent Western Blot analysis. 
 
K114 
The K114 fluorescent amyloid fibril binding assay was performed in 100 mM 
glycine buffer, pH 8.5 with 100 µM K114 (Tocris Bioscience) using an Olis-DM 45 
spectrofluorometer. Fluorescence was measured with an excitation wavelength of 380 
nm, and emission wavelength of 550 nm with a cutoff established at 530 nm for all assay 
endpoints. 
 
Electron Microscopy 
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Alpha-synuclein was added to carbon coated, 200mesh grids for 90 seconds. 
Grids were stained with 2% uranyl acetate for 45 seconds. Grids were dried overnight 
and imaged on a Hitachi H-600 transmission electron microscope (TEM). 
 
Immunofluorescence Microscopy 
Cells were allowed to adhere to Fibronectin (Sigma-Aldrich) treated glass 
coverslips and fixed with 3.7% formaldehyde (Polysciences) in 0.1 M piperazine-N, 
N'bis(2-ethanesulfonic acid) PIPES buffer at pH 6.8 for 15 min. Cells were then 
permeabilized for 20 minutes in PBS with 10% Normal Donkey Serum (NDS) and 0.5% 
saponin (Sigma-Aldrich). Staining with specific monoclonal or polyclonal antibodies was 
done in 10% NDS with 0.5% saponin for 20 minutes. Mouse-anti alpha-synuclein (BD 
Biosciences), EEA-1 (BD Biosciences), and LAMP-2 (BD Biosciences) were 
immunostained at 1:400 dilutions. Primary antibodies were secondarily labeled with 
fluorophore-conjugated donkey anti-mouse or donkey anti-rabbit antibodies (Jackson 
ImmunoResearch). Images were collected with a DeltaVision microscope (Applied 
Precision) equipped with a digital camera (CoolSNAP HQ; photometrics), using a 1.4-
numerical aperture (NA) 100X objective lens, and were deconvolved with SoftWoRx 
deconvolution software (Applied Precision). Structured Illumination images were 
collected on an OMX microscope (Applied Precision) and deconvolved and reconstructed 
using SoftWoRx software (Applied Precision). Tiff images and 3-dimensional 
reconstructions were generated using Imaris software (Bitplane). 
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Image Analysis 
 Deconvolved images were analyzed for colocalization of Galectin-3 (Gal-3) with 
LAMP2 and Early Endosome Antigen-1 (EEA-1) signal by use of the Surpass Mode of 
the Imaris software package (Bitplane). 
 
Statistical Analysis 
Results are presented as mean + standard error of the mean. ANOVA was used to 
compare between different experimental groups. All statistical analyses were performed 
using InStat 3.0 (GraphPad Software). p<0.05 was considered statistically significant. 
 
 
 
Results 
Characterization of Alpha-synuclein Aggregate Preparations 
Alpha-synuclein aggregates were generated by resuspending recombinant 
lyophilized protein followed by agitation for three days at 37°C.  Prior to agitation, 
purified recombinant alpha-synuclein ran at a molecular weight of slightly less than 50 
kD on a non-denaturing gel.  The three day incubation altered the electrophoretic 
mobility of the protein in a non-denaturing gel in two ways. First, the primary band in the 
solution exhibited less electrophoretic mobility than the presumably monomeric form of 
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the protein (Figure 1A).  Second, we also observed the appearance of a number of bands 
which migrated below the primary band.  Both of these changes may represent altered 
structural changes in alpha-synuclein induced during incubation or may also represent a 
multimeric form of alpha-synuclein which is induced during incubation.  Under 
denaturing conditions, all of these bands resolved to the expected ~15 kilodalton (kD) 
molecular weight of alpha-synuclein (Figure #10A). We also performed glutaraldehyde 
crosslinking to further define the high molecular weight species of alpha-synuclein 
induced by our incubation conditions.  Incubation induced the formation of high 
molecular weight species of alpha-synuclein observable following glutaraldehyde 
crosslinking (Figure #10B). These higher molecular weight species were not observed 
following glutaraldehyde crosslinking of freshly resuspended alpha-synuclein (Figure 
#10B). We also characterized our incubated protein with the dye K114, which can be 
used to measure amyloid fibrils in solution. We observe that incubation induced the 
formation of fibrillar structures, as measured by an increase in K114 fluorescence relative 
to freshly resuspended alpha-synuclein (Figure #10C) (p<0.01). Similarly, transmission 
electron microscopy of wt alpha-synuclein (with or without a 3 day incubation at 37°C) 
revealed fibrillar structures only following incubation. No such structures were detected 
in the absence of incubation (Figure #10D). These analyses revealed that this protocol 
induces a heterogeneous combination of fibrillar and oligomeric species of alpha-
synuclein. We will refer to this heterogeneous population of alpha-synuclein species as 
“aggregates”. 
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Figure #10: Alpha-synuclein aggregate characterization. A. Wild-type alpha-synuclein 
aggregates were generated using in vitro purified protein. Recombinant lyophilized 
alpha-synuclein was resuspended and followed by constant agitation for three days at 
37°C. The aggregates generated in this fashion were run on a non-denaturing gel (left) or 
denaturing gel (right), fixed and stained with Coomassie brilliant blue. B. Following 
incubation for 3 days as described, alpha-synuclein preparations were fixed with 
glutaraldehyde at the indicated concentration for 15 minutes at room temperature. C. 
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K114 analysis of alpha-synuclein which was freshly resuspended or incubated as 
described. Emission was measured at 550 nm. Error bars represent the standard error of 
the mean of 3 readings. Results are representative of at least three independent 
experiments (* indicates a P value <.01). D. Transmission electron micrograph of alpha-
synuclein preparations from freshly resuspended protein or after 3 days of incubation as 
described. Scale bars = 500 nm.  
 
Alpha-synuclein aggregate exposure leads to rupture of endocytic vesicles 
Galectin-3 is a sugar binding protein which recognizes beta-galactoside sugars 
which are normally only present on the exterior leaflet of the plasma membrane and the 
interior leaflet of intracellular vesicles [151]. Galectin-3 relocalization has therefore been 
utilized as a tool to identify ruptured vesicles in studies of bacteria and viruses which rely 
on vesicle rupture to enter the cytoplasm during infection [54, 126, 142]. To test the 
hypothesis that alpha-synuclein can induce the rupture of intracellular vesicles following 
endocytosis, we transduced human SH-SY5Y neuroblastoma cells and the rat 
dopaminergic neuronal N27 cell line with a retroviral vector expressing mCherry-
Galectin3 (chGal3). We treated these cells with the alpha-synuclein aggregates described 
in Figure #10. Incubation of N27 or SH-SY5Y cells stably expressing mCherry-Gal3 
(N27chGal3, SY5YchGal3) with alpha-synuclein aggregates induced a pronounced 
redistribution of chGal3 in both cell lines. While in the absence of aggregate exposure, 
chGal3 maintained a diffuse cytoplasmic localization in both cell lines; incubation with 
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alpha-synuclein aggregates for 24 hours induced the relocalization of chGal3 to 
intracellular, punctate structures (Figure #11). This relocalization suggests that alpha-
synuclein aggregates are able to disrupt the integrity of intracellular vesicular membranes 
following endocytosis. Treatment of cells with freshly resuspended (monomeric) alpha-
synuclein did not induce relocalization of chGal3 (Figure #12), suggesting that non-
monomeric forms or aggregated forms of alpha-synuclein are responsible for vesicular 
rupture under these conditions. 
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Figure #11: Alpha-synuclein aggregates induce discrete Galectin-3 puncta: SH-
SY5Y and N27 cells stably expressing chGal3 were treated with alpha-synuclein 
aggregates for 24 hours.  In both cell lines a relocalization from the diffuse, untreated 
state can be clearly visualized after 24 hours. This relocalization is indicative of 
intracellular vesicular rupture. Images are representative of at least three independent 
experiments.  
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Figure #12: Alpha-synuclein monomers do not induce Galectin-3 localization: 
N27 and SH-SY5Y cells stably expressing chGal3 were incubated with freshly 
resuspended alpha-synuclein for 24 hours. Treatment of these cells with freshly 
resuspended alpha-synuclein did not induce the redistribution observed at an equivalent 
concentration of alpha-synuclein aggregates (see Figure #11). 
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Alpha-synuclein aggregates induce the rupture of lysosomes  
 Previous studies of adenovirus found that protein VI mediated vesicle rupture 
occurs more frequently in vesicles positive for the endosomal marker Early Endosome 
Antigen 1 (EEA1), than in those positive for the lysosomal marker, Lysosomal 
Assosiated Membrane Protein-1 (LAMP-1) [126]. We similarly assessed the nature of the 
ruptured vesicles induced following alpha-synuclein incubation. Unlike the case of 
vesicles ruptured by protein VI, we observed the vast majority of chGal3 positive vesicles 
induced following incubation with alpha-synuclein aggregates were positive for the 
lysosomal marker, LAMP2 (Figure #13A), while very few chGal3 positive vesicles 
showed EEA1 staining above background (Figure #13B). This observation was 
confirmed by quantitative analysis of the amount of LAMP2 or EEA1 signal present in 
individual chGal3 puncta (7.43% of chGal3-positive vesicles exhibited EEA1 staining 
above background levels, whereas 91.98% of these vesicles exhibited LAMP2 staining 
greater than secondary antibody alone (Figure #13C). This suggests that, following 
endocytosis, alpha-synuclein induces the rupture of vesicles which are predominantly 
lysosomes, in contrast to the case of protein VI, which more frequently ruptures vesicles 
containing positive for EEA1 [126]. 
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Figure #13: Alpha-synuclein aggregates induce lysosomal rupture.  A. SH-SY5Y chGal3 
cells (red) treated with alpha-synuclein aggregates exhibit colocalization between chGal3 
and LAMP2 (green). The area shown in the white box in the upper left panel is enlarged 
in the other three panels. B. SH-SY5Y chGal3 cells (red) treated with alpha-synuclein, 
which does not induce colocalization between chGal3 and EEA1 (green). The area shown 
in the white box in the upper left panel is enlarged in the other three panels. C. 
Quantitative analysis of the colocalization of fluorescent intensity of EEA1 or LAMP2 
staining in individual chGal3 puncta identified using Imaris image analysis software. 
7.43% of chGal3-positive vesicles exhibited EEA1 staining above background levels, 
whereas 91.98% of these vesicles exhibited LAMP2 staining greater than secondary 
antibody alone. Forty images were collected for each group. More than 190 individual 
puncta were analyzed for each group. 
 
Alpha-synuclein localizes to areas of vesicular rupture in cells 
 We next determined if alpha-synuclein localized to ruptured vesicles by directly 
labeling alpha-synuclein aggregates with the Dylight 488 N-hydroxysuccinimide (NHS)-
ester [137]. When fluorescently labeled alpha-synuclein aggregates were added to SY5Y 
chGal3 cells, ruptured vesicles containing alpha-synuclein were clearly evident in these 
cells 24 hours later (White Arrows, Figure #14). However, we also observed chGal3 
puncta which did not contain detectable alpha-synuclein signal (Red Arrow, Figure #14). 
This association of alpha-synuclein with ruptured vesicles was confirmed in live cell 
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imaging experiments, in which alpha-synuclein and chGal3 remain associated during 
brief intracellular trafficking events (Movie S1). 
 
 
Figure #14: Labeled alpha-synuclein colocalizes with chGal-3 in neuronal cell lines. SH-
SY5Y chGal3 cell exposed to Dylight 488 conjugated alpha-synuclein aggregates for 24 
hours. The white box in the upper left panel is enlarged in the other three panels to 
demonstrate colocalization of alpha-synuclein and chGal3. White arrows show vesicles 
demonstrating colocalization between chGal3 and alpha-synuclein. The red arrow 
highlights a ruptured vesicle that does not appear to contain alpha-synuclein. 
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To better assess the localization of alpha-synuclein within ruptured vesicles, we 
performed structured illumination microscopy (SIM). SIM utilizes pattern based imaging 
of a specimen to generate reconstructions of the specimen with resolutions below the 
diffraction limit of light microscopy (~200 nm) [22]. When reconstructions of N27 cells 
incubated with alpha-synuclein were analyzed, alpha-synuclein was frequently observed 
to associate with the periphery of chGal3 positive vesicles, frequently forming arced or 
circular localizations (Figure #15). In some cases, alpha-synuclein formed an individual 
arc at the periphery of discrete ruptured vesicles (panel 2, Figure #15). In other cases, 
alpha-synuclein clustered in a series of circular localizations suggesting the presence of 
alpha-synuclein in a multivesicular compartment (panel 1, Figure #15). Additional 
examples of the intravesicular localization of alpha-synuclein are shown in Figure S2. 
The arced localization of alpha-synuclein at the vesicular periphery was also evident in 
three dimensional modeling of these reconstructions (Movie S2).  This is consistent with 
the idea that luminal alpha-synuclein induces membrane curvature that causes the rupture 
of these vesicles. Collectively these results demonstrate that following entry into target 
cells, alpha-synuclein aggregates are present in endocytic vesicles which have been 
ruptured. As these vesicles are not present in the absence of alpha-synuclein aggregates, 
we conclude that alpha-synuclein mediates the rupture of these vesicles. 
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Figure #15: Structured Illumination Microscopy (SIM) of alpha-synuclein mediated 
vesicle rupture.  N27chGal3 cells were exposed to Dylight 488 conjugated alpha-
synuclein aggregates for 48 hours. Cells were fixed and imaged using a structured 
illumination fluorescent microscope, allowing the images to be reconstructed with a 
resolution below the diffraction limit of light microscopy. The boxed area in the left 
panel is enlarged in the two panels to reveal the intraluminal localization of alpha-
synuclein.
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CHAPTER FOUR 
FOLLOWING LYSOSOMAL RUPTURE, AGGREGATED ALPHA-SYNUCLEIN 
INDUCES A CATHEPSIN B DEPENDENT INCREASE IN REACTIVE OXYGEN 
SPECIES (ROS) 
 
Abstract 
Here we examine the downstream consequences of the addition of alpha-
synuclein aggregates.  A critical aspect of our model of the cellular mechanism for PD 
pathogenesis is the connection between E/L rupture and ROS induction.  Lysosomal 
rupture may be an early event in the apoptotic cascade and mitochondrial release of pro-
apoptotic factors may be a consequence of previous lysosomal destabilization [152].  It 
has been shown that the rupture, particularly of lysosomes, leads to an induction of ROS 
in a cathepsin dependent manner [27, 152].  We are able to show in both neuronal cell 
lines an increase in the generation of ROS along a temporal scale similar to that observed 
in gal-3 puncta formation. Aggregate size also played a role in determining ROS 
generation. This increase in ROS is shown to be almost completely cathepsin B 
dependent as pre-administration of a selective cathepsin B inhibitor ameliorates the 
several fold increase seen in ROS. Demonstration that the ROS being generated was 
specific to mitochondria was shown by using a redox-sensitive form of Green Fluorescent 
Protein (GFP) (RO-GFP). 
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Introduction 
Intracellular rupture of lysosomes leads to the release of cathepsins in addition to 
other proteins as well.  Lysosomes are organelles that contain a wide variety of proteases 
(cathepsins) that help to maintain the turnover of membrane proteins and other 
macromolecules found in the cell [153].  Lysosomal processing capacity diminishes 
progressively over the lifespan of an animal [154, 155], and lysosomal malfunction is 
associated with age-related neurodegenerative disorders [155-158]. Inhibition of 
lysosomal enzymes has been shown to lead to abnormal protein accumulation and 
aggregation, synaptic loss, as well as neurodegeneration in laboratory models [159-161].  
Addition of purified cathepsin B and cathepsin D can generate significant 
increases in mitochondrial ROS production [152].  Mitochondrial dysfunction in PD has 
also had the attention of the PD field in recent years [71, 162-164]. In addition to MPP
+
 
there are several other environmental toxins that have the ability of to target mitochondria 
to create Parkinsonian symptoms [165, 166].  In human PD patient tissue samples of the 
SNpc  there is a substantial decrease in the activity of mitochondrial complex I of the 
electron transport chain (ETC) [167]. This decrease in activity is thought to be specific to 
PD patients and seems to reflect oxidative damage to complex I [168, 169].  Other 
cellular components in the SNpc of PD patients: lipids, proteins and DNA also have been 
found to be damaged by oxidative stress [170]. The source of this oxidative stress is 
largely mitochondrial. For the majority of eukaryotic cells, the electron transport chain 
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(ETC) is found in the mitochondrial membrane.  Even under basal conditions, the ETC 
can leak up to 2% of all electrons as ROS, and when cells are exposed to a number of 
extracellular stressors intracellular production of ROS increases [152].    
The physical proximity of mitochondrial DNA (mtDNA) to the site of ROS 
generation probably makes them an even more vulnerable target. The 
mitochondrial genome encodes 13 proteins involved in the mitochondria 
respiratory chain, 7 of which are involved in the formation of complex I. The 
number of mtDNA mutations present in clonally expanded clusters of SNc 
mitochondria is positively correlated with age and negatively correlated with 
cytochrome oxidase activity (a marker for functional respiratory activity). Their 
clonal nature argues that these mutations are due to the expansion of a somatic 
mutation, not a genetic mutation present at birth. Because many of these mtDNA 
mutations impair ETC function, they are likely to contribute to the loss of SNc 
DA neurons. [71] 
There seems to a very plausible connection between lysosomal rupture and mitochondrial 
oxidative stress.  
 
 Cathepsins have been shown to have a decreased immunofluorescent staining in 
post-mortem PD brains when compared with age-matched controls [153].  This alteration 
in cathepsin level was found to be most prominent in neurons found in the SNpc that 
contained alpha-synclein inclusionis [153]. This led us to hypothesize that one of the 
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cathepsins may be playing a role in the downstream consequences of alpha-synuclein 
aggregate inducing lysosomal rupture.  In order to measure the ROS level of the two 
neuronal cell lines we used 2', 7’-dichlorodihydrofluorescein diacetate (H2DCFDA), a 
cell-permeant dye.  It is a fluorescein derivative that has its acetate groups cleaved by 
intracellular esterases and when oxidized it becomes converted to a highly fluorescent 
version.  The presence of fluorescence is indicative of ROS detection.  While this is a 
reliable test, it does not specifically measure ROS generated by the mitochondria. In 
order to further validate our findings as well as obtain more specific data concerning the 
location of ROS generation we used reduction-oxidation sensitive green fluorescent 
protein (roGFP) [171, 172].  This protein uses a modified version of GFP. It has a 
mitochondrial targeting sequence with two cysteine residues in the beta-barrel structure.  
The oxidation state of each cell can be individually measured using roGFP as the 
oxidation state of the thiols present in the roGFP molecule will determine the fluorescent 
properties of the sensor.        
 
 
Material and Methods 
Cell Lines and reagents 
The human neuroblastoma cell line, SH-SY5Y, and the human monocyte cell line 
THP-1 were obtained from the American Type Culture Collection (ATCC). The rat 
dopaminergic neuronal cell line was a kind gift from Dr. Anumantha Kanthasamy [16]. 
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SH-SY5Y cells were maintained and differentiated with 50 mM all L–trans Retinoic acid 
every 48–72 hours in Dulbecco's modified Eagle's medium (DMEM) supplemented with 
10% fetal bovine serum (FBS)(Hyclone) and 100 IU/mL penicillin, 100 µg/mL 
streptomycin and 10 µg/mL ciprofloxacin. THP-1 cells were maintained in Roswell Park 
Memorial Institute (RPMI) 1640 media, supplemented with 10% FBS, 100 IU/ml 
penicillin, 1 mg/ml streptomycin, 0.25 µg/ml amphotericin B, non-essential amino acids, 
1 mM sodium pyruvate, 10 mM HEPES buffer and 2 mM glutamine. The rat 
dopaminergic cell line N27 was cultured in RPMI media with the same additives used in 
the DMEM. Cells were maintained in a 37°C incubator with 5% CO2.  
 
Alpha-synuclein 
 Full length alpha-synuclein and E46K mutant alpha-synuclein were purchased 
(rPeptide) and the lyophilized protein was rehydrated to a concentration of 1 mg/ml. 
alpha-synuclein was incubated for 3 days at 37°C in PBS with 100 mM NaCl under 
constant agitation followed by aliquoting and storage at −80°C. Aggregates were 
fluorescently labeled with Dylight 488 N-hydroxysuccinimide (NHS)-ester fluorophores 
(Thermo Scientific), according to the manufacturer's protocol prior to use. 
 
 
Live Cell Imaging 
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Images were acquired on a Deltavision deconvolution microscope equipped with 
a Weather Station™ chamber utilized to maintain the cells at 37° C at 5% CO2. Images 
were acquired using a Cascade 2 EMCCD (Photometrics) and deconvolved and 
reconstructed using SoftWoRx software (Applied Precision). Tiff images and 3-
dimensional reconstructions were generated using Imaris software (Bitplane). 
 
ROS Assay 
All N27 and SH-SY5Y cells were plated at 100,000–200,000 cells per well in a 
black 96-well plate (Costar) in RPMI or DMEM with 10% fetal bovine serum (FBS). 
Following 1 hour of serum starvation the cells were incubated with the ROS-sensitive 
fluorophore 2, 7-dichlorofluorescein diacetate H2DCFDA (DCF; Invitrogen) at 10 µM for 
1 hour per the manufacturer's protocol followed by two washes with phosphate-buffered 
saline (PBS). If pretreated with cathepsin B inhibitor, cells were incubated with 100 µM 
CA-074Me (EMD Biosciences) or dimethylformamide (DMF) as vehicle control for 1 
hour following H2DCFDA incubation. Alpha-synuclein aggregates were added at a 
concentration of 3 µg/ml in accordance with previous concentrations and the Volpicell-
Daley protocol [150]. Fluorescence intensity of oxidized DCF was measured over the 
course of 72 hours, at an excitation wavelength of 485 nm and an emission wavelength of 
520 nm, on a fluorescent plate reader (Biotek). Results are presented as background 
subtracted values (background was defined as cells that were not loaded with DCF). 
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RoGFP assessment of mitochondrial ROS 
RoGFP2 fused to a mitochondrial targeting sequence (mRoGFP) was obtained 
from S James Remington (University of Oregon). The open reading frame was inserted 
into lentiviral vectors containing a puromycin resistance cassette and vector stock was 
used to transduce parental SH-SY5Y cells. Cells stably expressing mRoGFP were 
selected in DMEM containing 5 µg/ml puromcyin. Cells were imaged in DMEM lacking 
phenol red (Invitrogen) at 90 second intervals. The basal oxidation state of individual 
cells was assessed for 6 minutes. 4 mM Dithiothreitol was added after 6 minutes to define 
the minimum oxidation state of the imaged cells. After 6 minutes (4 time points) in DTT, 
the cells were quickly washed with PBS and 300 µM Aldrithiol was added to define the 
maximal oxidation state of the imaged cells. The relative oxidation state of each cell was 
calculated by fixing the minimum oxidation state observed in the presence of DTT to 0 
and the maximum oxidation state observed in the presence of Ald to 1, as previously 
described by Guzman et al [173]. Averages are from an analysis of a minimum of 15 
cells from each treatment group that was analyzed. 
 
 
Results 
Alpha-synuclein aggregates induce a cathepsin dependent increase in ROS  
The rupture of endosomes and lysosomes is associated with an increase in cellular 
ROS in cells [27, 174-176]. Therefore we asked if vesicle rupture by alpha-synuclein 
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aggregates could similarly induce an increase in ROS in cells. We utilized the redox 
sensitive fluorophore H2DCFDA to monitor the ROS generated in neuronal cells 
following treatment with alpha-synuclein aggregates. Treatment with alpha-synuclein 
aggregates induced a significant (P<0.05 1-way ANOVA with Bonferroni post-hoc) 
increase in the fluorescence observed in both the N27 and SH-SY5Y cells (Figure #16A, 
16B). To determine if this increase in ROS was related to the release of activated 
cathepsins from ruptured lysosomes, we incubated cells with alpha-synuclein aggregates 
in the presence of the cathepsin B inhibitor, Ca074-me. Ca074-me significantly abrogated 
the increase (P<0.01) in ROS observed following treatment with alpha-synuclein 
aggregates (Figure #16A, 16B). These experiments collectively demonstrate that alpha-
synuclein can induce a cathepsin B dependent increase in ROS in target cells. In order to 
corroborate this data, we utilized SH-SY5Y cells stably expressing a redox sensitive form 
of GFP [171, 172] targeted to mitochondria to determine if the ROS induced by alpha-
synuclein specifically altered the redox state of the mitochondrial membrane in affected 
cells. This protein allows for the measurement of the mitochondrial oxidation state in 
living cells relative to the minimum oxidation, which is measured by the addition of a 
strong reductant, dithiothrietol (DTT), and to the maximum oxidation, which is measured 
by the addition of a strong oxidant, aldrithiol [173]. The initial oxidation state for each 
cell can then be calculated relative to the minimal and maximal oxidation states defined 
by these two conditions. As shown in Figure #16C, cells treated with alpha-synuclein 
aggregates exhibited increased mitochondrial oxidation relative to control treated cells. 
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Figure #16: Alpha-synuclein aggregates induce a Cathepsin-B dependent 
increase in ROS. SH-SY5Y (A) or N27 (B) cells loaded with the fluorescent substrate 
H2DCFDA reagent and incubated in the presence or absence of alpha-synuclein 
aggregates with or without treatment with the cathepsin B inhibitor Ca-074Me. Error bars 
represent the SEM of triplicate samples. C. SH-SY5Y cells stably expressing 
mitochondrially targeted roGFP1 were incubated for 72 hours with alpha-synuclein 
aggregates and the oxidation state of the mitochondria of individual cells was assessed at 
described in the text. Error bars represent the SEM of 15 or more cells analyzed for each 
treatment group. * p<0.001. 
 
 
Larger aggregates generated by the E46K alpha-synuclein mutant fail to induce 
vesicular rupture and ROS production  
We next examined the ability of the genetically-linked PD alpha-synuclein 
mutant, E46K, to induce vesicular rupture and ROS in target cells. When purified, 
recombinant E46K alpha-synuclein was subjected to the same incubation protocol as 
wild-type (wt) the E46K mutant exhibited reduced electrophoretic mobility compared to 
wt aggregates (Figure #17A). As with the wt, all of these bands resolved to the expected 
~15kD band under denaturing conditions (data not shown). Glutaraldehyde crosslinking 
revealed that higher molecular weight species of E46K alpha-synuclein were also present 
following incubation (Figure #17B). K114 analysis revealed that the E46K mutant had 
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more fibrillar content that wt alpha-synuclein incubated under the same conditions 
(p<0.01) (Figure #17C). Consistent with this observation, macroscopically visible 
aggregates were present in the E46K samples following incubation (data not shown). 
Fibrillar species were also readily detectable in these preparations using electron 
microscopy (Figure S3D). Thus, in following our aggregation protocol, E46K alpha-
synuclein formed fibrillar structures to a greater degree than that observed for wt alpha-
synuclein. 
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Figure #17: E46K aggregate characterization. E46K mutant alpha-synuclein was 
generated using in-vitro purified protein. Recombinant lyophilized E46K alpha-synuclein 
was resuspended and constantly agitated for three days at 37°C. A. The aggregates 
generated in this fashion were run on a non-denaturing gel, fixed and stained with 
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Coomassie brilliant blue. E46K alpha-synuclein ran at a higher molecular weight than the 
wild-type alpha-synuclein on the non-denaturing gel. B. Following incubation for 3 days 
as described, E46K alpha-synuclein preparations were fixed with glutaraldehyde at the 
indicated concentration for 15 minutes at room temperature. C. The fibrillar content of 
E46K aggregates was assessed using K114 staining. E46K aggregates had significantly 
more fibrillar content than wt aggregates following identical treatement (*P<0.01). 
Results are representative of at least three independent experiments D. TEM image of 
E46K alpha-synuclein fibril 
 
We next asked if E46K alpha-synuclein preparations were as competent at wt 
alpha-synuclein to induce ROS in target cells. E46K alpha-synuclein aggregates induced 
significantly less ROS than wt alpha-synuclein in N27 and SH-SY5Y cells (Figure 
#18A, 18B), (p = 0.039 in N27, p = 0.024 in SY5Y). However, this degree of ROS 
induction was still significant relative to control treated cells (p<0.001 in N27 p<0.016 in 
SY5Y). When cells treated with these E46K alpha-synuclein aggregates were analyzed 
by fluorescent microscopy, we observed that a significant amount of the alpha-synuclein 
stain localized to large aggregates that appeared too large to enter the cell via 
endocytosis. These aggregates did not induce chGal3 relocalization (Figure #18C). 
Collectively, these results demonstrate that large alpha-synuclein amyloid aggregates do 
not induce chGal3 relocalization and preparations which contain larger protein aggregates 
are less effective at inducing ROS in target cells. The most likely explanation for this 
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observation is that large aggregates are unable to enter the endocytic compartment and 
therefore do not induce the rupture of lysosomes and subsequent cathepsin dependent 
mitochondrial stress. 
 
 
Figure #18: Large aggregates generated by E46K alpha-synuclein mutant are unable to 
efficiently induce vesicle rupture and ROS. (A) SH-SY5Y or (B) N27 cells were loaded 
with H2DCFDA reagent and incubated with wt or E46K alpha-synuclein. Error bars 
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represent the SEM of triplicate samples. Results are representative of at least three 
independent experiments. C. Purified recombinant E46K alpha-synuclein aggregates 
were added to N27 chGal3 cells for 24 hours, stained with an alpha-synuclein specific 
antibody (green) and imaged as in previous experiments. Results are representative of at 
least three independent experiments. 
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CHAPTER FIVE 
GALECTIN-3 MAY BE PLAYING A ROLE IN THE CELLULAR SECRETION 
MECHANISM OF ALPHA-SYNUCLEIN 
 
Abstract 
In order to perpetuate the PD pathology, alpha-synuclein must be spread in cell-
to-cell manner. This would create a positive feedback loop of neurodegeneration. We 
have shown that aggregated alpha-synuclein induces lysosomal rupture and generates 
ROS as part of the downstream effects.  For a molecule to be an agent of pathology it 
must exit the host cell and complete a transfer from the first cell to the second cell, 
gaining accessing to the second cell by crossing the plasma membrane. Alpha-synuclein 
has shown the ability to exit from cells utilizing various mechanisms, specifically 
exocytosis. Different aggregation state of alpha-synuclein have been discovered in CSF 
and in blood plasma [51].  Cellular stressors, including: serum deprivation, lysosomal 
inhibition and oxidative agents have been shown to lead to an increase in the release of 
alpha-synuclein [177]. These data also holds true in cell culture models; aggregates of 
alpha-synuclein have been found in the media of neuroblastoma cells as well as rat 
primary cortical neurons [144, 177].  We believe that gal-3 may be playing a role as we 
have data supporting the idea that gal-3 protein levels in neuronal cells decrease when 
exposed to aggregated alpha-synuclein.  Here we are also able to provide live-cell movies 
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as well as fixed cell images of cell-to-cell transfer of alpha-synuclein aggregates and 
colocalized gal-3.          
 
Introduction 
 During times of cellular stress neurons have been shown to secrete alpha-
synuclein [177]. It is unclear whether this is a protective mechanism, an attempt to purge 
the cell of a toxic protein.  Interestingly, the alpha-synuclein recovered in the media 
demonstrates more oxidative modifications than other forms found intracellularly 
indicating a preferential release of damaged and aggregation prone alpha-synuclein [177].  
Exosomes are small vesicles that break off from the endocytic machinery and manifest in 
the extracellular space. A membrane already envelops the contents of an exosome, which 
provides two benefits: ease of fusing with the plasma membrane of a recipient cell, and 
protection from enzymatic degradation in the extracellular space. The risk for 
extracellular degradation is apparent as unprotected alpha-synuclein has been shown to 
be degraded by matrix metalloproteinase 3 (MMP-3) in the extracellular space [178, 
179].  Exosomes have been shown to be associated with secreted alpha-synuclein [121, 
180, 181].  The exact form of alpha-synuclein may be irrelevant, as the secretion leads to 
the propagation of PD pathology.  Uncontrolled expulsion of alpha-synuclein also may 
occur during cellular lysis from a dying cell.  
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 It is well known that alpha-synuclein aggregates are toxic to cells, particularly in 
an in-vitro cell culture setting [182] and when neuronal cells are stressed they have been 
shown to release more alpha-synuclein [177].  We have been able to demonstrate that the 
short-term administration of alpha-synuclein aggregates to N27 and SH-SY5Y cells can 
lead to increased secretion of alpha-synuclein. The basal level of secretion for 
neuroblastoma cells and other cultured neurons has been described as a “regulated, low-
probability event” [177].  Exposure of these neurons to alpha-synuclein aggregates for 
twenty-four hours leads to an increase in secretion into the cell culture medium as 
analyzed by western blot.  Collectively, these experiments define a pathway by which 
pathology may be induced in cells during the spread of alpha-synuclein associated 
pathology observed in PD.   
 
 
 
Material and Methods 
Cell Lines and reagents 
The human neuroblastoma cell line, SH-SY5Y, and the human monocyte cell line 
THP-1 were obtained from the American Type Culture Collection (ATCC). The rat 
dopaminergic neuronal cell line was a kind gift from Dr. Anumantha Kanthasamy [16]. 
SH-SY5Y cells were maintained and differentiated with 50 mM all L–trans Retinoic acid 
every 48–72 hours in Dulbecco's modified Eagle's medium (DMEM) supplemented with 
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10% fetal bovine serum (FBS)(Hyclone) and 100 IU/mL penicillin, 100 µg/mL 
streptomycin and 10 µg/mL ciprofloxacin. THP-1 cells were maintained in Roswell Park 
Memorial Institute (RPMI) 1640 media, supplemented with 10% FBS, 100 IU/ml 
penicillin, 1 mg/ml streptomycin, 0.25 µg/ml amphotericin B, non-essential amino acids, 
1 mM sodium pyruvate, 10 mM HEPES buffer and 2 mM glutamine. The rat 
dopaminergic cell line N27 was cultured in RPMI media with the same additives used in 
the DMEM. Cells were maintained in a 37°C incubator with 5% CO2. 
 
Alpha-synuclein 
Full length alpha-synuclein and E46K mutant alpha-synuclein were purchased 
(rPeptide) and the lyophilized protein was rehydrated to a concentration of 1 mg/ml. 
alpha-synuclein was incubated for 3 days at 37°C in PBS with 100 mM NaCl under 
constant agitation followed by aliquoting and storage at −80°C. Aggregates were 
fluorescently labeled with Dylight 488 N-hydroxysuccinimide (NHS)-ester fluorophores 
(Thermo Scientific), according to the manufacturer's protocol prior to use. 
 
1-methyl-4-phenylpyridine (MPP+) Treatment 
 MPP
+
 was obtained from Sigma-Aldrich in a powdered form. It was dissolved in 
DMSO and added to the RPMI cell culture media at a concentration of . This treatment 
lasted 24 hours after which the cells were washed briefly with PBS and new media added 
to the cell culture dish as well as “recipient” cells, N27chGal3.  These “recipient” cells 
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were left in co-culture for 48 hours, at which time the media was removed and the cells 
were fixed and imaged.  
 
Western Blot of Supernatant 
N27 and SH-SY5Y cells were exposed to 24 hour of alpha-synuclein aggregate 
exposure followed by a complete media change for another 24 hours and then the cell 
culture supernatant was collected.  2× sample buffer was added to the supernatant and 
equal amount of protein was loaded into a 10% non-denaturing gel for electrophoresis. 
Proteins were transferred to nitrocellulose membranes and detected by incubation with 
the primary alpha-synuclein antibody. The H3C monoclonal alpha-synuclein antibody 
developed by Julia George was obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD and maintained by The University of 
Iowa, Department of Biology, Iowa City, IA 52242. Secondary antibody conjugated to 
HRP (Thermo Scientific) was used, and antibody complexes were detected using 
SuperSignal West Femto chemiluminescent substrate (Thermo Scientific). 
Chemiluminescence was measured using a BioRad ChemiDoc XRS imaging system 
(BioRad) 
 
Immunofluorescence Microscopy 
 Cells were allowed to adhere to Fibronectin (Sigma-Aldrich) treated glass 
coverslips (Fisher Scientific) and fixed with 3.7% formaldehyde (Polysciences) in 0.1 M 
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piperazine-N, N'bis(2-ethanesulfonic acid) PIPES buffer at pH 6.8 for 15 min. Cells were 
then permeabilized for 20 minutes in PBS with 10% Normal Donkey Serum (NDS) and 
0.5% saponin (Sigma-Aldrich). Staining with specific monoclonal or polyclonal 
antibodies was done in 10% NDS with 0.5% saponin for 20 minutes. Mouse-anti alpha-
synuclein (BD Biosciences) was immunostained at 1:400 dilution. Primary antibody was 
secondarily labeled with fluorophore-conjugated donkey anti-mouse antibody (Jackson 
ImmunoResearch). Images were collected with a DeltaVision microscope (Applied 
Precision) equipped with a digital camera (CoolSNAP HQ; photometrics), using a 1.4-
numerical aperture (NA) 100X objective lens, and were deconvolved with SoftWoRx 
deconvolution software (Applied Precision). Tiff images and 3-dimensional 
reconstructions were generated using Imaris software (Bitplane). 
 
Live Cell Imaging 
Images were acquired on a Deltavision deconvolution microscope equipped with 
a Weather Station™ chamber utilized to maintain the cells at 37° C at 5% CO2. Images 
were acquired using an Cascade 2 EMCCD (Photometrics) and deconvolved as described 
above. 
 
Image Analysis 
Deconvolved images were analyzed for quantification of Galectin-3 (Gal-3) 
signal by use of the Imaris software package (Bitplane). 
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Flow Cytometry 
 N27 and SH-SY5Y cells expressing mcherryGal-3 were plated in 6-well plates. 
N27 and SH-SY5Y cells expressing mcherryGal-3 and untagged GFP were also plated in 
6 well plates. Alpha-synuclein aggregates were added to the cell culture media at a 
concentration of 3µg/ml for 24, 48 and 72 hour time points.  Cell culture media was 
aspirated; cells were washed briefly with PBS, and then trypsinized.  Cells were 
resuspended in the appropriate cell culture media and spun at 5,000 rpm for 5 minutes.  
Media was aspirated and cells were resuspended in PBS and Flow Fixative (50/50 
volumetric mixture of PBS and 3.7% formaldehyde (Polysciences)). Cells were analyzed 
at the Loyola University Medical Center FACS Core Facility utilizing a LSRFortessa cell 
analyzer (BD Biosciences). For each sample in each experiment over 10,000 events were 
recorded and analyzed. All FACS analyses were performed using FlowJo (Treestar) 
software.     
 
Statistical analysis 
The data, wherever applicable, are presented as means + SEM and were analyzed 
using ANOVA p<0.05 was considered statistically significant.  
 
Results 
Alpha-synuclein aggregate treatment induces cells to secrete more alpha-synuclein 
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To determine the effects of in-vitro aggregated alpha-synuclein on N27 and SH-SY5Y 
cells production of endogenous alpha-synuclein we measured via non-denaturing western 
blot the amount of protein in the supernatant.  This western blot analysis took place after 
the cells had been treated for 24 hours with alpha-synuclein aggregates, washed and had 
the media replaced with untreated media for another 24 hour time span and then the 
supernatant was harvested and run on western. From Figure #19 it is clear that the 
addition of alpha-synuclein aggregates induces an increase in the amount of alpha-
synuclein in the supernatant. Whether this is due to an increase in production of alpha-
synuclein, a decrease in degradation or a fluctuation in the extrusion of alpha-synuclein 
into the supernatant is unclear.  
 
 
 
Figure #19. Alpha-synuclein aggregate treatment induces an increase in endogenous 
alpha-synuclein secretion. N27 cell supernatant was run out on a non-denaturing gel, as 
was SH-SY5Y cell supernatant. Both cell lines were treated with 3µg/ml of wild-type 
alpha-synuclein aggregates for 24 hours, washed and media replaced. The new media was 
collected after a span of 24 hours and run in conjunction with the untreated supernatants. 
These blot images are representative of three independent experiments.    
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Cell to cell transfer of alpha-synuclein induces vesicular rupture 
 To determine whether alpha-synuclein expressed from one cell could induce the 
rupture of vesicles in neighboring cells, we treated N27 cells stably expressing alpha-
synuclein (N27 alpha-synuclein) with the mitochondrial toxin MPP
+
 (1-methyl-4-
phenylpyridine), which is used to induce a Parkinson's like pathology in tissue culture 
[183]. Following MPP
+
 treatment, we added N27chGal3 cells to the culture and 
incubated these cells together for a period of 48 hours. In this mixed culture, 
colocalization of alpha-synuclein and chGal3 could indeed be observed. In the example 
shown in Figure #20, alpha-synuclein can be observed localizing to crescent shaped 
structures at the periphery of chGal3 positive vesicles. We therefore conclude that alpha-
synuclein expressed and released from eukaryotic cells can subsequently be internalized 
and induce vesicle rupture in a manner similar to what we observed with alpha-synuclein 
aggregates generated with recombinant protein.  
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Figure #20: Vesicle rupture following the cell to cell transfer of alpha-synuclein. N27 
cells stably expressing alpha-synuclein and treated with MPP
+
 for 24 hours. N27chGal3 
cells were then added to the culture and co-cultured for 48 hours. Cells were then fixed 
and stained for alpha-synuclein (green). The boxed areas in the left panel are enlarged to 
allow visualization of alpha-synuclein and chGal3 colocalization. 
 
 
Galectin-3 transfer with labeled alpha-synuclein aggregates 
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 While the experimental results shown in Figure #20 are compelling, we were 
very intrigued by the possibility of observing this translocation of alpha-synuclein in real-
time. According to the Brundin group, the direct transfer of alpha-synuclein aggregates 
had never been observed [17].  We treated SH-SY5Y cells that were expressing mcherry 
tagged galectin-3 with 3 µg/ml of Dylight 488 labeled alpha-synuclein aggregates for 24 
hours. After which the media was aspirated off, cells were washed and colorless media 
was added. Images were collected by an electron-multiplying charge coupled device 
(EMCCD) camera at five second intervals for 5 minutes.  In Movie 1 the aggregates are 
in green and the gal-3 puncta are in red. There are certain cellular locations which show 
the colocalization of ruptured lysosomes, as evidenced by the red (gal-3) puncta, with 
labeled alpha-synuclein. Several of these intracellular protein associations appear to 
move quickly and fluidly from one cell to another.         
 
 
Movie #1. Demonstration of alpha-synuclein associating with Galectin-3 puncta and 
transitioning from once cell to another. Live-cell movie of SH-SY5Y chGal3 cells that 
have been exposed to Dylight 488 conjugated alpha-synuclein aggregates for 24 hours. 
The chGal3 signal is red, and the labeled alpha-synuclein aggregates are displayed in 
green. Images were collected at five second intervals for five minutes. 
 
An unexpected decrease in mCherry-Gal-3 fluorescence  
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 While attempting to quantify the fluorescence of images taken in Figure #11 it 
was determined that the maximum fluorescence intensity of mCherry-Gal3 cells (N27 
and SH-SY5Y) treated with alpha-synuclein aggregates had values in the same range as 
the same cells that were untreated (data not shown).  This is a perplexing phenomenon as 
one of the tenets of fluorescent microscopy states that if the intracellular protein levels 
stay the same, then when the proteins aggregates they should exhibit a higher maximal 
intensity. This has held true for all previous studies in the lab, utilizing fluorescent 
microscopy [184, 185].  From this data we were interested in testing the intracellular 
levels of mCherry-Galectin-3 using flow cytometry before and after the addition of 3 
µg/ml wild-type alpha-synuclein aggregates. Flow cytometry was chosen as the method 
of inquiry because it is able to provide analysis of large quantities of cells and we were 
only interested in the mean fluorescent intensity (MFI) of the mCherry-Galectin-3 
channel. Cells were plated, aggregates were added for the specified time points, media 
was aspirated and cells washed with PBS and placed in flow fixative and run on a 
LSRFortessa (BD Biosciences). After three independent experiments where over ten 
thousand events were monitored for each experimental group we were finally able to 
deduce that following treatment with alpha-synuclein aggregates the MFI of intracellular 
mCherry-Galectin-3 was declining (Figure #21).  This trend could be seen beginning 
after 24 hours of treatment with wild-type alpha-synuclein aggregates and continued, but 
does not appear to increase, up to 72 hours.  Comparing each time point’s untreated 
group with the aggregate treated group gave us a significant (p>0.05) value. This data set 
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was very intruiging as, a paper had been recently published detailing the discovery that 
galectin-8 was playing a role in not only monitoring lysosomal integrity upon Salmonella 
invasion but when exposed to the intracellular environment galectin-8 activated 
antibacterial autophagy [54].  Galectin-8 and galectin-3 are both from the same family of 
cytosolic lectins, which led us to hypothesize that galectin-3 might have a dual function 
in the response to the lysosomes ruptured by alpha-synuclein. In fact, given the data we 
had collected in Figure #19 that alpha-syuclein was being vacated from the intracellular 
environment, we hypothesized that galectin-3 may be playing a role in the transfer of 
alpha-synuclein aggregates from cell-to-cell which was seen in Movie 1.   
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Figure #21: Decrease seen in the MFI of neuronal cells chGal-3 after the addition of 
alpha-synuclein aggregates. N27 cells are seen beginning at 24 hours and continuing 
over the course of 72 hours maintaining a decrease in the MFI of mchGal-3 after treated 
with alpha-synuclein aggregates. Over 10,000 events were run for each sample and 
values are + SEM. Data is representative of three independent experiments. *, p<0.05 as 
compared to N27 Gal3 untreated samples.    
 
The role of galectin-3 in the secretion/transfer of alpha-synuclein 
In order to test this hypothesis we created a stable dual fluorescent protein 
expressing cell line. N27 cells which expressed mCherry-Gal-3 and an untagged GFP 
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protein.  These cells would be able to help determine whether galectin-3 was playing a 
specific role in the transfer/secretion of alpha-synuclein or it was merely subject to a 
diffusion gradient and effluxed from the intracellular environment due to the small pores 
that have been attributed to alpha-synucleins’ interaction with lipid membranes [15, 16, 
18, 41, 42, 100, 105-107, 109, 115].  If the transport of alpha-synuclein was indeed being 
facilitated by galectin-3 then the data would show only a decrease in intracellular MFI 
values of mCherry-Gal-3 while the untagged GFP levels would stay the same. However, 
the elegant beauty of this experiment is that the data would also be able to demonstrate if 
The cells were plated and 3 µg/ml of alpha-synuclein aggregates were added.  The media 
was aspirated, cells were washed with PBS and cells were collected at the specified time 
points (24, 48 and 72 hours) and placed in flow fixative and run on a LSRFortessa (BD 
Biosciences).   
89 
 
 
 
 
Figure #22: Intracellular decreases are seen in both mCherryGal-3 and untagged GFP 
after the administration of unlabeled wild-type alpha-synuclein aggregates. N27 cells 
exhibit a non-specific decrease in fluorescence after being exposed to alpha-synuclein 
aggregates. There is a decrease seen at all three time points (24, 48 and 72 hours) in both 
fluorescent channels (mCherry and GFP). Values are means + SEM, from 3 independent 
experiments, with 10,000 events recorded per experiment. *, p<0.05 as compared to N27 
Gal3 and N27 Gal3 + GFP untreated samples.  
 
This data collected from the dual color expressing cells shows the same trend seen in 
Figure #21, the diminution of mCherry-Galectin-3 signal after 24 hours of exposure to 
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alpha-synuclein aggregates. This trend as seen in the previous figure continues for all 3 
separate time points (Figure #22).  However, the data provided due to the addition of the 
untagged-GFP clarifies the actions of both alpha-synuclein and galectin-3.  GFP levels, 
while not as robust as mCherry-Gal-3 levels in the untreated samples, also decrease 
significantly upon the addition of wild-type alpha-synuclein aggregates.  We took this as 
evidence that the addition of alpha-synuclein aggregates provided a non-specific method 
of efflux for intracellular proteins. As previously cited, alpha-synuclein has been known 
not only to bind and bend lipid membranes but also to create small pores in cellular 
membranes [15, 16, 18, 41, 42, 100, 105-107, 109, 115].  The creation of these pores is 
what we believe is leading to the efflux of mCherry-Gal3 as well as alpha-synuclein and 
this is evidenced by the non-specific decrease in GFP seen following the addition of 
alpha-synuclein aggregates. 
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CHAPTER SIX 
SUMMARY AND DISCUSSION 
 
Parkinson’s disease and Alpha-synuclein 
 Parkinson’s affects large numbers of people worldwide currently [5-7] and those 
numbers have been predicted to rise sharply in the coming years as large percentages of 
the population continue to age and life expectancy rates continue to increase. Genetic 
studies of small cohorts and families affected by early-onset and rapidly progressing 
forms of PD have led the biomedical focus to be placed on the protein, alpha-synuclein 
[34, 86, 115, 186, 187]. Neurodegeneration due to this nefarious protein is not limited to 
PD.  Other neurological conditions have been found to have proteinaceous underpinnings 
of neurodegeneration due to alpha-synuclein and they include: PDD, DLB, and MSA.  
All of these diseases have been termed synucleinopathies or Lewy Body Diseases (LBD) 
as the common theme uniting all of these conditions is the presence of alpha-synuclein 
protein inclusions, called Lewy Bodies.  The spread of these inclusions within the 
nervous system of patients has led to the proposal of the Braak hypothesis [117, 118, 
188] in which a systematic propagation of the pathology is seen through progressive 
stages affecting different areas of the CNS. This viral-like property of the alpha-synuclein 
92 
 
 
 
protein is reminiscent of the pathology of adenovirus protein VI described in detail by the 
Wiethoff lab [22, 26, 27, 126-128].  Also, protein VI and alpha-synuclein share a 
remarkably similar structure. These two factors combined to give us the foundation for 
our study: that alpha-synuclein due to its similar structure to adenovirus protein VI would 
have a similar membrane-rupturing function and closely-related downstream 
consequences of this rupture.              
 
. 
Summary of Results 
In the previously described experiments, we tested the hypothesis that alpha-
synuclein aggregates induce the rupture of lysosomes. This hypothesis was founded on 
the observation that alpha-synuclein and adenovirus protein VI can both induce the 
tubulation and rupture of synthetic membranes [22, 42, 126, 127]. Given that protein VI 
is the viral protein responsible for inducing vesicle rupture during infection [22, 26, 27, 
126-128], we hypothesized that alpha-synuclein may possess a similar activity that is 
relevant to its pathology. Utilizing the relocalization of Galectin-3 (Figure 2) as a marker 
of vesicular rupture [54, 138-141, 151], we demonstrate that alpha-synuclein aggregates 
can induce the rupture of vesicles in two neuronal cell lines: N27 and SH-SY5Y. We 
demonstrate that the ruptured vesicles induced by alpha-synuclein are positive for 
LAMP2 (Figure 4), and that the appearance of these ruptured vesicles correlates with the 
induction of a cathepsin B dependent increase in ROS in these cells (Figure 7). 
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The Wiethoff lab has previously shown that release of protein VI correlates with 
the rupture of cell membranes prior to, or upon reaching early endosomes [27, 127]. 
Early escape from endosomes may be favorable for human adenovirus 5, as it results in 
the release of fewer activated cathepsins into the cytosol and a reduced inflammatory 
response compared to other human adenovirus serotypes that enter cells by using 
different receptors [127]. Conversely, vesicle rupture by alpha-synuclein is likely not a 
property that provides selective advantage to the organism. Rather, it seems likely that 
this property may be an indirect and evolutionarily unintended activity of a protein that 
has likely evolved to perform a function other than vesicle rupture. Although it is 
possible that the alpha-synuclein aggregates used in our study do not precisely 
recapitulate the ability of toxic alpha-synuclein species to mediate vesicle rupture in PD, 
a number of other in vitro and in vivo studies collectively suggest lysosomal dysfunction 
may be a central aspect of PD pathology (reviewed in [94]). 
 
The Lansbury group has demonstrated that alpha-synuclein can induce both small 
membrane pores on artificial membranes, which allows for the diffusion of ions and very 
small molecules, as well as a more dramatic permeabilization at higher concentrations, 
allowing larger molecules and proteins to pass through the lipid bilayer [15, 189, 190]. 
Although our studies do not directly compare these two possibilities, the molecular 
weight of the mCherry-Gal3 fusion protein is much larger than the size limit of pore 
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diffusion reported in these studies, suggesting that membrane rupture, rather than pore 
formation, is required for the localization of chGal3 to vesicles ruptured by alpha-
synuclein. 
 
Biochemical analysis of the alpha-synuclein aggregates utilized in this study 
reveals the presence of both fibrillar and oliomeric species of alpha-synuclein (Figure 1). 
Future studies will be required to determine which forms of alpha-synuclein mediate 
vesicular rupture most efficiently. The aggregation prone alpha-synuclein variant E46K, 
which tended to form aggregates too large to enter the endocytic compartment (Figure 
8), did not induce ruptured vesicles to the same degree as wt alpha-synuclein, nor did it 
induce ROS levels equivalent to wt alpha-synuclein (Figure 9). This does not 
demonstrate that E46K alpha-synuclein has less pathological potential than wt alpha-
synuclein. In fact, the E46K mutation is linked to familial PD [86]. However, in the 
context of these experiments, we suspect that the tendency to self-associate in vivo into 
pathological species of alpha-synuclein is mimicked by the protocols employed here to 
induce the aggregatation of wt alpha-synuclein. When the E46K alpha-synuclein mutant 
was subjected to similar protocols, much larger species of aggregates were induced which 
allowed us to compare the relative pathological potential of large aggregates and small 
aggregates in our experimental system. This is consistent with a previous report 
suggesting that E46K has an increased propensity to assemble into larger, insoluble 
fibrils with an amyloid architecture [191]. We cannot exclude the possibility that the 
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reduced vesicular rupture and ROS induction by the E46K mutant is due to the E46K 
mutation. However, we favor the idea that these larger aggregates induced with the E46K 
variant were less toxic because they were too large to be internalized into target cells, 
preventing them from inducing the rupture of intracellular vesicles. 
 
The fact that chGal3 positive ruptured vesicles do not ubiquitously contain 
detectable amounts of alpha-synuclein suggests that alpha-synuclein has the capacity to 
dissociate from the endocytic vesicle following rupture, although we cannot exclude the 
possibility that these vesicles contained alpha-synuclein which was not detected in our 
experiments. Similarly, not all alpha-synuclein signal we observed colocalized with 
chGal3. This may indicate alpha-synuclein which has dissociated from a vesicle 
following rupture or alternatively may be alpha-synuclein still existing within the 
vesicular compartment which has not induced vesicle rupture. While we cannot 
distinguish between these possibilities using this assay, the observation that alpha-
synuclein localizes to the periphery of ruptured vesicles is consistent with the idea that 
alpha-synuclein induces membrane curvature capable of inducing the rupture of these 
vesicles. 
 
It is also worth noting how the pathological pathway identified here might be 
relevant to the propagation of alpha-synuclein pathology in vivo. Work from other labs, 
taken with the data presented here, suggests a mechanism by which alpha-synuclein 
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mediated lysosome rupture may perpetuate the propagation of alpha-synuclein pathology. 
Specifically, Alvarez-Erviti and coworkers have demonstrated that lysosomal dysfunction 
and stress increase the release of alpha-synuclein containing exosomes [180]. Danzer and 
colleagues have demonstrated alpha-synuclein containing exosomes induce more 
pathology than recombinant aggregates [192]. Taken together, the observations here and 
in these studies suggest a mechanism by which continued vesicular rupture by alpha-
synuclein may not only exert toxic effects on a given cell but may also perpetuate the 
propagation of alpha-synuclein pathology to neighboring cells. 
 
Although the data presented here utilize cell lines to demonstrate lysosomal rupture and 
ROS induction, it is worth nothing that others have reported clinical observations 
consistent with the pathway identified. Reduced cathepsin and LAMP immunoreactivity 
has been observed in nigral neurons in PD patients [153], consistent with the idea of 
vesicle rupture and cytoplasmic diffusion of lysosomal contents. The role of 
mitochondrial dysfunction is also well established in PD [148]. 
 
 
Here, we define the pathway by which alpha-synuclein escapes the vesicular 
compartment and induces toxicity in tissue culture cells. Future studies are needed to 
determine the degree to which α-synuclein mediated lysosomal rupture affects the 
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propagation of PD pathology in primary neuronal cultures, animal models and individuals 
affected by PD and other synucleinopathies. 
 
 
Figure #23. Schematic of molecular mechanism for alpha-synuclein pathology.  
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Future Directions 
 While the data presented here is compelling, we recognize that it was obtained 
through the use of cultured cells. Cultured cells provide an expedient method to 
investigate molecular mechanisms of pathology. Albeit, an occasionally unreliable one.  
The future of this project is defined by several broad aims. Foremost of these aims will be 
the replication of this or similar experiments in another model. Primary murine neuronal 
culture has been recently established as a new standard in the veracity and applicability of 
results from cultured cells.  This type of cell culture method has been a staple of the 
Surmeier and Lee labs and has been utilized in a number of key findings in high impact 
journals [13, 57, 69, 71, 150, 173, 193].  Another model that would provide great insight 
into the molecular mechanisms that we have detailed here would be the single inoculation 
of alpha-synuclein aggregates into the striatum of wild-type nontransgenic mice as 
detailed by Luk and colleagues in a 2012 paper published in Science [123].  These studies 
would be done with the ultimate goal being to investigate age-matched PD and control 
human specimens for the presence of galectin-3.  A second broad aim which the genesis 
of has been this current study is to analyze the efficacy of cathepsin-B inhibitors. The 
data presented in Figure #16 demonstrates that aggregated alpha-synuclein leads to the 
generation of high levels of ROS by neuronal cells and that these high levels of ROS can 
be almost completely ameliorated by the addition of the cathepsin-B inhibitor, Ca-074me.  
A variety of cathepsin inhibitors have been explored for efficacy in tumor survival and 
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metastasis [194-197].  Yet, there seems to be a relatively large knowledge gap concerning 
cathepsins and neurodegenerative disease.  Cathepsin D has been shown to be 
upregulated in the caudate nucleus [198], and to affect alpha-synuclein processing [199].  
An Italian group has very recently shown that the addition of Ca-074me in their hands 
also leads to an amelioration in ROS production as well as Interleukin-1 beta (IL-1β) 
[200].  These studies were performed on human monocytes yet the similarities in 
experimental design and data speak to the veracity of the finding.  Cathepsin inhibition 
could also be a straightforward way to halt further downstream consequences and 
hopefully neuronal cell death in PD patients.  The final broad aim that would be very 
helpful to elucidate, given the findings stated here, is to determine the role that 
endogenous galectin-3 plays in the pathology of PD. Galectin-3 has been detected 
intracellularly and extracellularly in a variety of tissues [201].  Expression of galectin-3 
in the CNS has not been extensively investigated, but microglia have been shown to 
express galectin-3 [202, 203].  Neuronal expression remains to be seen.  However, this 
provides an interesting possibility as galectin-3 has been shown to be a marker for 
intracellular vesicle rupture.  Alterations in the expression level of galectin-3 may be one 
of the key missing pieces to the identification of patient populations at-risk for PD.  
Modulation of galectin levels may provide the cell with a way to secrete/escape the 
pathology of aggregated alpha-synuclein.  It is these several broad aims which represent 
the next series of questions needed to move this project forward.    
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Clinical Implications 
 The data presented herein, are applicable to variety of clinical settings and offer 
novel information regarding alpha-synuclein and galectin-3 as a potential biomarker and 
arbiter of downstream consequences leading to neurodegeneration. Our data, 
demonstrating galectin-3 as a marker for lysosomal rupture in neuronal cells and an 
increase in cathepsin-B dependent ROS following alpha-synuclein aggregate treatment 
implicates cathepsin-B as a possible therapeutic target in the treatment of Parkinson’s 
related pathology.  In addition, reliance on galectin-3 could be a beneficial biomarker for 
the diagnosis and prognosis of PD and other synucleinopathies.   
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